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SUMMARY
The well-established herbicide, asulam (methyl%4- 
aminobenzenesulphonylcarbaraate; M&B 9O57) is used widely 
for control of weed species including docks and bracken.
The compound resembles sulphonamides in structure.
Most of an oral dose of asulam is eliminated from rats 
mainly in the urine (75/o) and faeces (l9^) within 2h hours. 
Biotransformation in the intact animal is-similar to the 
N-acetylation of some sulphonamides. The major metabolite 
is N -acetylasulam which is excreted rapidly in the urine 
(l5fo male; 9^ female) and also appears in faeces ( ?^o). 
Induction of rats with asulam does not effect overall metabolism 
and excretion except that decarbamoylation is increased in 
the gut. N^-acetylsulphanilamide is also produced ( zfo) 
by decarbamoylation in the gut. N -acetylasulam formation 
in vitro is located in the cell-membrane fraction of liver.
Asulam is not eliminated in the bile ( 1^ dose) 
in vivo. No binding spectrum is obtained with microsomal 
cytochrome Ph^O, Continuous perfusion through liver for 
6 hours does not increase biliary elimination, but at least 
three water-soluble unidentified compounds (^.5/°) are formed 
in plasma.
In contrast to the in vivo state asulam causes rapid 
oxygen uptake in vitro with microsomes producing an isolatable 
colored metabolite (\max = 330 nm) which contain^Ai ring- 
substituted hydroxy sulphonamido and nitrogen substituted 
carbamate groups. Mass spectrometry shows this not to be
2-hydroxyasulam.
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CHAPTER 1
INTRODUCTION
INTRODUCTION
Asulam (methyl 4-aminobenzenesulphonylcarbamate; l) 
(M&B 9057) is a well established herbicide with many 
important uses.
0
h ^n -^^^^ s o ^-n h -c -o c h^
(I)
The compound belongs to the class of sulphonamides 
or N- substituted aminobenzenesulphonamides although it 
possesses structural elements common to both carbamates and 
sulphonamides. The strongly polarising effect of the 
sulphonyl and carbamate groups which change the chemical 
nature of the adjacent nitrogen effectively puts asulam 
into a separate class named the benzenesulphonylcarbamates.
The development of a new herbicide 
{a ) Preliminary studies
Asulam was first synthesised in I96I at May & Baker 
Limited, one of a series of benzenesulphonylcarbamates (ll) 
prepared as part of a project on contact herbicides.
Marked herbicidal properties were found when the alkyl group
;
(II)
R was methyl and the aromatic substituent X was nitro (x = 
4-NOg), methyl carbamoyl (x = U-NHCOOCH^) or amino (x = 4-NHg), 
pre-emergence activity comparing well with that of the common 
carbamate herbicides (soundy, Cottrell and Carpenter, 1963; 
Bell, Cottrell and Heywood, I965). The most promising com-
pound of the series proved to be asulam, which was selected 
for further development (Heywood and Leeds, I968),
(b) Herbicidal properties
The development of asulam, marketed as a 40^ aqueous 
solution of the sodium salt and trade-named Asulox, showed 
that the product could be used successfully in a number of 
crops. Docks (Rumex spp.) were susceptible (Lescar, 197l) 
in the presence of rye-grass, which was unaffected; also 
grass weeds in sugar-cane crops, were susceptible (Tuckett 
and Ball, I968; Cooke, Parker and Williams, 1969; Goderdham, 
1973)• Many grasses were also controlled, including Johnson 
grass (sorghum halepense) (Eashin and Helpert, I973), batria 
grass (Hlnojo, Cossio and Bardudi, 1973), crab grass (Blair 
and Holroyd, 1973) and several broad-leaved weeds (Ram and 
Talbert, 1973). A major breakthrough in the development 
of asulam was achieved when good control of brabken was 
reported (Holroyd, Park and Rowland, 1970)
The use of asulam for control of bracken
(a) The bracken problem
Bracken (Pteridinium aqUilinium ) is a common weed growing 
in temperate climates mainly in woodlands and fell country.
The weed has been shown to cause a number of harmful effects 
in the environment. When ingested, it can cause sickness or 
death in cattle (Sorenson, 1972) and in horses (Evans, Evans 
and Roberts, 1951). It also inhibits the growth of grasses 
by releasing phytotoxins into the soil (Gliessman, 1973) and 
thus by infestation of large areas of countryside can reduce 
the amount of potentially useful grasses available for grazing.
The toxic response caused by bracken poisoning in animals 
takes a number of different forms. Extracts prepared from
bracken have been shown to be toxic to the fruit-fly 
(Drosophila spp.) (Bendix, 19?4) and to many experimental 
animals (Thomas, 1973). The cattle disease enzootic hematuria, 
can occur when there is heavy grazing and cattle are 
encouraged by the lack of palatable grasses to feed on bracken 
(Sorenson, 1972). Toxicity in cattle resembles radiation 
sickness (Schofield, 1947; Evans, Evans & Hughes,1954) with the 
occurrence of bone marrow hyperplasia and terminal multiple 
haemorrhaging in cases of severe poisoning. Bracken staggers, 
a disease of horses (Evans, Evans and Roberts, 1951) which 
has also been produced experimentally in rats (Weswig, Freed 
and Haag, 1946),is characterised by a thiamine deficiency 
which can be overcome by administration of vitamin Bl. In 
the rat bracken causes a depression of erythrocyte formation, 
an increase in circulating heparin and synthesis of an 
abnormal fibrinogen component in the blood (Evans and Howell,
1963),.
Bracken is also known to be carcinogenic. Ifhen rats 
were fed a diet containing 34^ by weight of dried bracken 
fronds for 64 days during a 5-month study, malignant tumours 
were present in the small intestine of nearly all the 
animals (Evans and Mason, I965). Similar results were 
demonstrated in rats and other experimental animals with 
purified extracts (Evans, I968; Evans et al, T 969). The 
carcinogenic principle of bracken has been shown to be elim­
inated in the urine of animals fed on bracken fern since 
pellets containing solids from the acidic fraction of urine 
implanted into the bladders of mice caused carcinomas to 
develop (Pamukan, Olson and Price, I966). Passage of bracken 
toxicity into milk has been observed after ingestion of extracts 
from bracken fern by cows and mice (Evans, Jones and Main-
waring-Burton, 1972). The toxicity was transferred via 
the milk into the progeny. Harmful effects on the embryos 
of pregnant mice fed bracken fern have also been observed 
(Yasuda, Kihara and Nishimura, 1974).
Warnings about the possible human health hazard of 
bracken fern have been made (Evans et al, 1971) and much 
work has been directed in finding the actual chemical species 
involved in the toxic response to animals (Saito et al, 1975;
Evans and Osman, 1974). Toxic principles are known to be 
leached from the developing fronds on the fern. These 
toxins, which are also highly phytotoxic, could contain 
chemical species similar to those encountered in the car­
cinogenicity tests in animals. A route could be envisaged 
for the spread throughout the environment, in rain-water run­
off and leachates, of specific carcinogenic compounds con­
tained in bracken so posing a serious risk of water pollution 
in bracken infested areas.
(b) The mode of action of asulam
Asulam has sufficiently effective herbicidal properties 
for the efficient control of bracken (Holroyd, Park and 
Rowland, I970). The retention of asulam on the leaves, after 
spraying bracken with Asulox at the recommended rates (Soper,
1972), can be increased by the addition of a wetting agent.Di additio 
Tween 20 was found to double the penetration of asulam to the 
bracken frond (Babiker and Duncan, 1974) and other additives 
including urea are being Investigated (Freest, 1975).
The compound, once absorbed, acts systemically and is 
taken up by the roots and leaves, distributed through the 
plant by translocation and concentrated in the growing buds
on the bracken rhizome (Carpenter, and Clarke, 1973). Growth 
at these points is inhibited by a complex mechanism which 
does not involve carbohydrate utilization (Martin, Williams 
and Raymond, 1972). Translocation of the drug is important 
for activity as in tolerant plants penetration of asulam is 
limited and movement restricted almost entirely to the treated 
leaves, where the drug is deactivated by degrading enzymes 
(Carpenter and Clarke, 1973).
The relationship of asulam to the carbamates
Asulam can formally be associated most closely with the 
carbamate herbicides(ill) in which the nitrogen is linked
0
^^V-NH-C-OR
(m )
directly to the benzene ring but the strongly polarising 
effect of the sulphbnyl group in asulam may modify properties 
of the carbamate group,
(a) The chemistry and metabolism of the carbamates 
The chemical properties of the 0-esters of carbamic 
acid,also known as urethanes or carbamates (iv), of which 
the N-alkyl derivatives (v) form an important sub-group, 
reflect the presence of ester and amide groups. The alkpxyl
0 0 
I 1 I
HgN-C-OR R -NH-C-OR
(IV) (V)
group is replaced on heating with ammonia giving urea whilst 
metallic salts, corresponding with those from amides, are 
formed with evolution of hydrogen when sodium is added to
an ethereal solution of a carbamate (Kraft, I890). The 
sodium derivatives are rapidly decomposed by water and 
react with halogen compounds (e.g. methyl iodide) to give 
the N-substituted carbamates (v). Hot aqueous acids or 
alkali decompose carbamates to the alcohol, carbon dioxide 
and ammonia.
Carbamates are hydrolysed in mammals giving a carbamic 
acid and alcohol which may be further oxidised or conjugated. 
Alkyl carbamates (iV) would yield carbamic acid and eventually 
urea (vi) (williams, 1959).
0 0
HgN-C-OR------- > HgN-C-OH + R-OH------ > oxidised or conjugated
(IV) i
HgN-C-NHg
(VI)
Methyl carbamate (HgNCOOCH^) when injected into rats 
at 0,5 g/kg is completely metabolised, only 5-10^ of the 
unchanged drug appearing in the urine (Soyland and Papadopoulos, 
1952). The narcotic drug ethyl carbamate is also almost 
completely broken down in rats only 4^ appearing unchanged 
in the urine in 24 hours (Boyland and Rhoden, 1949).
Further studies with ^^C-labelled drug showed that 90^ of 
the radioactivity appeared in the respiratory gases, mainly 
as carbon dioxide in 24 hours (skipper et al, 1948).
(b) The carbamate herbicides
Herbicidal activity of a group of substituted carbamates 
(e.g. chlorprofham (VII)) was discovered in 1924 (Frieson).
0 ^ C H ^
^"^-NH-C-O-CH
c T  ^ C H ,
( V I I )
Further research to find an effective non-toxic agent 
with pre-emergence activity (Templeman and Sexton, 19^5;
1946) lead to the development of the carbamate herbicides 
propham (ill; X=H; Rs-CHfCH^jg'Chlorpropham (ill; X=3-Cl; 
R=-CH(CH^)2 ), barban (ill; X=3-C1; Rii-CH^C^C-CH^Cl), 
chlorbufam (ill; X=3-Cl; R=-CH(CH^)c=CH), Swep (ill; X=
3,4-diCl; R=CH^) and carbetamide (ill; X=H; R=-CH(CH^)C0NHC2H ^ ).
The mode of action of carbamate herbicides is by 
inhibition of cell division in the meristems of shoots and 
roots (Ennis, 1948) and photolysis of water in the Hill 
reaction. Carbamates have been used against a wide variety 
of weeds in several crops (Martin, 1973), but their use 
more recently has declined in the face of more competitive 
products. They are very non-toxic to birds, fishes and 
mammals (Metcalf, 1971) in contrast to some competitive 
products, which have been withdrawn from use, and their 
inherent safety may become more relevant in the face of 
stringent laws on environmental protection.
The metabolism of N-substituted carbamates in soil 
micro-organisms has been studied (Kaufman and Kearney,
1963). Chlorphropham (VIl) was hydrolysed in soil or in 
aqueous media to give carbon dioxide, isopropanol (vill) 
and 3-ohloroaniline (IX).
0 CH.
C l ^  ci
(VII) (IX) (VIII)
l4When herbicide was used which contained a C-label in 
the aromatic ring, further degradation of the benzene 
nucleus was observed, showing a further complex metabolic
- b -
route in soil micro-organisms.
The sulphanilamide group of asulam
The benzenesulphonylcarbamates can be regarded as 
carbamate derivatives of a substituted sulphonamide (ll). 
Asulam therefore becomes the methyl carbamoyl derivative
0
SOg-NH-C-OR
(II)
of sulphanilamide since X = 4-amino, and can be expected 
to exhibit some properties of the N^-substituted amino- 
benzenesulphonylcarbamates.
(a) The metabolism of sulphanilamide 
Sulphanilamide (x) is one of the sulphonamides, a 
group of drugs widely used in chemotherapy. Metabolism 
of the sulphonamides has been reviewed extensively (Williams,
(X)
1959» Reimerdes and Thumin, 1970).
The major reaction of sulphanilamide is conjugation 
of the free aromatic amino group with acetate to give a 
substituted amide. The reaction is controlled by enzymes 
found in mammals, which have been called N-acetyltransferases 
(Lipman, 1945). Acétylation was found to be dependent on 
a sufficient supply of "active acetate" (Marshal, Cutting 
and Emerson, 1937), which could be increased by adding 
pyruvic or lactic acid (Klein and Harris, 1938). The
active principle for acétylation was later found to be 
the important metabolic intermediate acetyl co-enzyme A 
(Lipman, 1945). The reaction can be summarised as a two- 
step transfer of acetate,
CH^CO --- X + CoASH------> HX + CoAS-COCH^
CoASH = co-enzyme A
CH^COX = acetate source
CoAS-COCH^ + HY --------- > CoASH + CH^CO-Y
(Y = -NHC^Hj^SOgNHg)
Acétylation has been observed in bean plants (Rudd- 
Jones and Vignall, 1955) and in many animal species 
(Bridges and Williams, I963). In the rat, sulphanilamide 
forms minor metabolites, which correspond to attack by 
acetate at either or both of the available nitrogen atoms 
(Boyer, Saviard and Dechavassine, I95O), The major 
metabolite is N^-acetylsulphanilamide (lO^ of dose) (Xl), 
but appreciable amounts of N^-acetylsulphanilamide (5^ 
of dose) (XIl) and N^^N^-diacetylsulphanilamide (2^ &f 
dose) (XIIl) are also formed.
CH^CO-HN^-^~~^ SOg-NHg SOg-NH^-COCH^ CH^CQ-HN^-^"^SOgN^H-COCH,
(XI) (XII) (XIII)
When the proportion of metabolites obtained in the 
rat is compared with studies in other species some diff­
erences are evident. Firstly, Boyer et al indicates 
the rabbit is a much better acetylator than the rat,
50^ of a dose of sulphanilamide being acetylated compared 
with 17^ in the rat. Secondly, the dog is a poor acetylator 
(Bray et al, 1950) all the acetylated form appearing as 
the N^-acetylated metabolite (15'^ of dose). The presence
of enzymes which can deacetylate sulphonamides has been 
demonstrated in the dog (Ockerblad and Carlson, 1939) the 
chicken (Shaffer and Bieter, 1950) and in other species 
(Krebs, Sykes and Bartley, 194?). Krebs has suggested 
that the levels of the acetylated product and the 
unacetylated drug may reach an equilibrium value corresponding
4
to the activities of the two types of enzyme. N - 
acetylsulphanilamide is excreted unchanged in the rabbit, 
rat and guinea-pig (Bray and James, I960),
Sulphanilamide is also susceptible to oxidation and 
conjugation with sulphate and glucuronic acid (williams,
1959)* The ethereal sulphate output of rabbits was in­
creased after administration of sulphanilamide (Smith and 
Williams, 1948). The metabolite from urine, representing 
6-12^ of the dose, was identified as 4-aminobenzenesulphonamide,
3-hydrogen sulphate (XIV). The oxidation of sulphanilamide 
also occurs in the rabbit (Dobson and Williams, 1946) and 
in humans (williams, 194?) whence it was confirmed that 
the oxidised intermediate was 3-hydroxysulphanilamide (XV).
S0„-NH„ H „ N S O „ - N H ,
HOHO^S-0
(XIV) ' (XV)
The preferred conjugation of sulphanilamide seems to 
be sulphation for evidence of the common glucuronic acid 
conjugation is doubtful (Williams, 1959)» Sulphanilamide 
does not increase the glucuronic acid output in man 
(Gilligan & Beck,194$) and the same is true for rats (Scudi and 
Robinson, 1941). However, when 3-hydroxysulphanilamide 
is fed to rabbits it is partly excreted as the glucuronide
conjugate (williams, 1943) which may indicate that there 
exists some concentration-dependent mechanism for conjugation.
During the acétylation of sulphanilamide a secondary 
product can be formed by oxidation of the acetylated 
compound in the side-chain. An intraperitoneal dose of 
100 mg/kg sulphanilamide yielded N^-sulphamoylphenylglycol- 
amide and N^-sulphamoyloxamic acid (15-20^ of dose) in the 
urine of rabbits (Fries, Kiese and Lenk, 19?l)*
(b) Sulphonamides and the sulpha drugs 
The reactions of sulphonamides have mostly been 
studied with reference to the use of sulpha drugs in chemo­
therapy and consequently their metabolism has been established 
in a large number of species (Williams, 1959; Reimerdes 
and Thumin, 1970). One reaction of interest has been 
that which tends to reduce the effectiveness or deactivates 
thé drug in vivo.
A common example of deactivation is cross-resistance 
in bacteria. Throughout the development of sulphonamides 
discovery of resistant strains of bacteria has been common. 
Resistance seems to flourish in places where excessive 
use of sulphonamides is practiced. The spread of drug- 
resistant strains seems to be linked with the ability of 
bacteria to modify their genetic material in strongly 
selective environments, by mutation and bacterial conjugation 
(Watanabe, 1967; Pitton, 1972).
It might be possible, by the above mechanism, that 
resistance to sulphonamides may be formed and transferred 
from non-pathogenic bacteria to pathogenic strains by 
continual exposure of the safe strain to other compounds 
of similar structure such as the benzenesulphonylcarbamates
(il). Certain assurances have now been made that asulam 
shows no such trend towards increased resistance to sulphon­
amides in the gut microflora of young calves (Griffin, Ball 
.& Twitchett, 1975) •
Some historical importance has been attached to the 
discovery in 1935 that the drug Prontosil (XVl) (4-(2 ,4 - 
diaminophenylazo)-benzenesulphonamide) becomes active only 
after it has been metabolized by intestinal micro-organisms 
in the gut wall (Gingell and Bridges, 1971; Northey, 1940).
The reaction produces sulphanilamide in the gut, by azo 
reduction, which is absorbed and exerts a therapeutic effect.
NHg
(XVI)
Hydrolysis of an amide group is a common reaction of 
intestinal micro-organisms and several sulphonamides with 
an amide linlcage may be susceptible. N -acetylsulphanilamide 
is not hydrolysed upon incubation with rat caecal micro­
organisms (Scheline, 19^8) or with other strains of intestinal 
bacteria (Solain and Scheline,•1972). Hydrolysis of N^- 
acetylsulphisoxazole (XVIl) a metabolite of sulphisoxazole 
(Gantrisin), has been shown with several species of intestinal 
bacteria (Uno and Kono, I96I),
^COCH^
'* (XVII)
k
Even though N -acetylsulphanilamide is unaffected by 
the gut microflora several structurally related compounds
are known to undergo hydrolysis . p-Acetamidobonzoic acid 
(XVIIl) is hydrolysed by rat caecal micro-organisms (scheline, 
1968) and by Aerobacter aerogenes (solain and Scheline, I972). 
Phenacetin (XIX) is also hydrolysed at the N^-position in 
these micro-organisms.
C H ^ C O -H N -^ ~ y -C O O H  C H ^ C O -H N -^ ^ ^ ^ O C ^ H ^
(XVIII) (XIX)
Physical chemistry of the benzenesulphonylcarbamates in 
solution
The sulphonamido nitrogen of the benzenesulphonyl­
carbamates (11) is affected by the electron withdrawing
0
f!
S 0 2—NH—C — OR
(II)
properties of the adjacent sulphonyl group so that the 
electronic structure around the nitrogen is delocalized 
and the dissociation constant of the labile hydrogen is 
increased. Consideration of the acid dissociation 
constants of N-acetylbenzamide (XX) (pKa = 10,15) and 
N-acetylbenzenesulphonamide (XXl) (pKa=4,72) illustrates 
that the sulphonyl group increases activity of the nitrogen 
in this position (Exner and Janek, 1975)»
   J 0
^J-CO-KH-C-CE^ ^SO^-NE-g-CH^
(XX) (XXI)
It was shown that the total substituent effect on a
DIAGRAM 1
Ionization of asulam in solution
Percentage ionised species for 4-amino (o) and 1-amino (x) groups 
of asulam calculated from the Henderson-Hasselbalch equation,
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mesomeric effects of the two substituent groups. In the 
case of sulphonamides, the combination of sulphonyl and 
carbonyl groups increased the acidity at nitrogen.
The acid dissociation constants of asulam (methyl, 
U-aminobenzenesulphonylcarbamate) and M&B 8882 (methyl,
4-nitrobenzenesulphonylcarbamate), have been measured at 
4.82 and 3.95 respectively (Heywood and Leeds, I968), A 
marked increase in acidity compared to the sulphonamide 
drugs (pKas 10.4 to 5.4) (Bell and Roblin, 19^2) illustrates 
the degree of activation. As a consequence of their 
increased acidity the benzenesulphonylcarbamates form 
stable salts with alkali and alkaline earth metals and amines.
The free aromatic 4-aifiano group of the benzenesulphonyl­
carbamates also may contribute significantly to overall 
behaviour in solution. The 4-amino group in asulam has 
a pKb of 12.2. Together the acidic sulphonamide nitrogen 
and the basic aromatic amino group impart amphoteric 
properties and asulam can behave as a zwitterion with an 
isoelectric point of 3.3 in aqueous solution (Heywood and 
Leeds, 1968).
The fate of benzenesulphonylcarbamates in mammals may 
be, in part, controlled by the direct affect of. pH in localized 
areas of absorption, distribution and metabolism. The 
Henderson-Hasselbalch equation for calculation of percentage 
of ionized asulam mdecules at a given pH yields values of 
40^ ionized at pH 4.5 and 99.5^ ionized at pH 7.5 (physiological 
pH). (Diagram 1; for derivation anddata see Appendix 1) 
Absorption of asulam in the gut becomes favourable when 
asulam is most lipophilic «« in the_ unionized state. Therefore 
most of the asulam molecules will tend to absorb in the
upper intestine or duodenum (Parke, 1968),
The fate of asulam in animals
It is most usual for herbicides, such as a_sulam, to be 
tested for metabolism only in the target crop but their 
fate in animals is becoming more relevant in the face 
of increasingly stringent legislation.
Asulam is eliminated rapidly from lactating cows 
(Lim, 1968) and goats (Unsworth, 1975) with negligible 
accumulation in the milk. In rats, 60^ of an oral dose 
of 1.0 mg/kg is eliminated in the urine after 6 hours and 
after 24 hours this rises to 75^ with 19^ in the faeces 
(Heijbroek, unpublished). Effectively quantitative recovery 
of a dose of 10 mg/kg asulam given to rats is obtained 
in the excreta after 187 hours (Filer, I968),
Accumulation of residual drug in the tissues of the 
rat is essentially absent after repeated dosing at 1.0 
mg/kg for 3 and 7 days-less than 1^ of the original dose 
appearing in the carcass, with levels in blood of less than 
300 ppm (Heijbroek, unpublished),
Asulam is metabolised to N^-acetylasulam (XXIl) in 
the rat (Heijbroek, 1972) and goat (Unsworth, 1975) but 
conversion is small in the rat, much of the dose being 
excreted unchanged.
(XXII)
In addition to N^-acetylasulam, N^-acetylsulphanilamide
has been suspected as a minor metabolite (Heijbroek, 
unpublished).
Summary
Asulam has good herbicidal activity against many weed 
species, including bracken, docks and broad-leaved weeds 
in sugar-cane.
It resembles carbamates and sulphonamides in structure, 
though is more acidic in solution. The carbamate and 
sulphonamido groups may undergo chemical changes in 
animals by metabolism.
Expected reactions of metabolism are acétylation of 
the 4-amino group, hydroxylation of the benzene ring 
followed by conjugation, and hydrolysis of the carbamate 
group.
Possible problems in the understanding of the fate 
of asulam are based on its lack of reactivity in animals.
In particular, points that could be raised are the following:-
(1) How rapidly is it metabolised?
(2 ) Does metabolism have to be induced?
(3 ) Does asulam penetrate to the sites of metabolism?
(4) Can asulam interact with the microsomal mixed- 
function oxidases? . . .
(5 ) Is asulam resistant to metabolism or are there 
other inhibiting factors?
Preliminary single-dose studies in rats (Filer, 1968; 
Heijbroek, 1972) have shown that asulam is not metabolized 
rapidly therefore further points require investigation.
CHAPTER 2
FATE OF A SINGLE DOSE OF ASULAM IN UN-PREMEDICATED
ANIMALS
1. Introduction
Metabolic studies with asulam in animals (Unsworth,
1975» Heijbroek, 1972) have shown a low extent of reactivity 
and a preference for formation of acetylated metabolites.
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N -acetylasulam and N -acetylsulphanilamide have both been 
isolated by preparative thin-layer chromatography from the 
urine of rats (Heijbroek, unpublished). Additional 
studies on absorption and elimination of asulam in animals' 
(Filer, 1968 ; Heijbroek, 1972) using and ^^C-labelled
drug, demonstrate good absorption from the gut and speedy 
elimination of asulam and its metabolites in the urine.
Further experiments with rats were proposed to 
confirm original findings and to investigate more thoroughly 
the absorbtion of drug from the gut, after a single oral 
dose, of radiolabelled asulam. For this purpose, ^^C- 
asulam with uniform label in the ring (Archer & Clow,
1978) was thought to be the most biologically-stable labelling 
position.
Reports on significant advances in biliary cannulation 
(Scheline, I965) prompted the use of this technique to 
study the elimination of asulam into the gut from the 
bile duct, after initial absorption into the blood, as 
the compound's molecular weight and polarity may make it 
a suitable candidate for excretion in bile. Biliary 
excretion of compounds of molecular weight greater than 
250 is known to be significant (Hirom et al, 1972).
Extensive voiding of the dose in bile and subsequent 
metabolism by the gut microflora or gut wall could lead 
to reabsorption of metabolites but significant levels of 
drug in the faeces of rats given a single oral dose of
asulam (Heijbroek, 1972) may only be caused by poor absorption
of the dose. Administration of the dose intravenously
could therefore further demonstrate the significance of
elimination in the bile and metabolism by the gut.
2. Experimental Section 
/ \ l4(a ) C-asulam
Labelled drug was synthesised by a seven step 
procedure (Archer and Clow, 1978) from uniformly 
labelled benzene (Radiochemical Centre, Amersham, Bucks.) 
(Appendix 2).
Specific activity of asulam-(ring^^c) was measured 
at 2.62 mCi/mM (batch DVA 2613B). This batch was used 
undiluted. Purity was measured initially at 99*7^ by thin- 
layer chromatography on silica gel thin-layer plates 
(Polygram SIL Q/CV^^^)with development in ethyl acetate/ 
methylene chloride (40;60, v/v). After storage at 4°C 
for two years, purity measured by thin-layer chromatography 
on silica gel plates (Polygram SIL G/UV )with development
254
in ethylacetate/diethyl ether/ acetic acid (glacial) (5 :5 :1, 
by volume), had dropped slightly to 98.9^, Batch DWA 2613B 
was used for all single-dose experiments.
(b) Preparation of dosing solution
Radiolabelled asulam of a specific activity 2.62 mCi/ 
mM (Batch DWA 2Ô13B; 99*7^ pure) was used throughout.
An accurately weighed quantity of asulam-(ring ^^C) was 
carefully dissolved in a stoichiometric amount of freshly 
prepared M NaOH, in an open weighing boat. The solution 
was washed into a volumetric flask with water delivered 
dropwise from a Pasteur pipette and the solution made up 
to volume.
(c) Animals
Male and female albino rats of the Sprague-Dawley 
strain (Huntingdon) were used in the weight range 150-200 g.
(d) Experiments with oral dosing
(i ) Animal housing
Rats were housed either individually or in single-sex 
groups of three in a controlled environment at 20°C 
(jencons Metabowl Mark 3, see plate l) and maintained on 
Spratts No. 2 expanded pellets and water ab libitum.
The apparatus enabled the separate collection of urine 
and faeces and enabled continuous monitoring of exhaled 
air during the experiment by trapping CO^ in 2-ethoxyethanol/ 
ethanolamine (l:l, v/v).
(ii) Dosing
An accurately determined volume (l.O ml) of asulam- 
(ring dosing solution (2 mg/ml) was delivered orally
to each rat using a glass Tubercillin syringe. The rate 
of administration was about 10 mg/kg.
(iii) Collection of samples
Urine, faeces and 00^ trapping fluid were collected 
24 hours after dosing. Animals were sacrificed after 
24 hours and carcasses stored at -20°C. Washings were 
collected at the end of each experiment,
(e ) Experiments with biliary cannulation
Each rat vas anaesthetized with diethyl ether and a 
mid-line incision made along the ventral surface of the 
animal. A polypropylene cannula (PorteK PPIO) was 
inserted into the common bile duct close to the liver and 
fastened securely with silk suture. The free end of the 
cannula was brought through the abdominal wall.
PT 1
T V - V T V O  PTTTnTE<S
T H E  •T’^ 'V r O V S  MT^'TABOWL MARK 3
A short time after the operation, the rat was dosed 
orally with asulatn-( ring ) ( 10 mg/kg) and then placed 
in a specially designed restraining cage similar to that 
described by Scheline (1966). Bile duct cannulated rats 
were maintained in these cages for 24 hours after operation 
and bile, urine and faeces collected. Exhaled 
air was not collected.
(f) Experiments with intravenous dosing
A solution of asulara-(ring in isotonic saline
was administered to rats through the tail vein. Single­
sex groups of 3 J animals were housed in a Jencons Metabowl 
Mark 3 and urine, faeces and exhaled air collected,as 
previously described, after 24 hours.
(g) Analysis of samples
(i) Liquid Scintillation Counting
Radioactive samples were counted in a Tracerlab 
Corumatic 200 Spectrometer by the liquid scintillation 
method. Scintillation mixtures were either purchased 
or prepared in the laboratory /naphthalene(400 g); 2,5- 
diphenyloxazole (25 g); 1,4-bis /2(5-phenyloxazoyl)7 benzene 
(2.5 g); dioxan (2778 ml); xylene (1667 ml); methanol 
(556 ml^/. Samples were standardised by the internal 
Qiethod using n-hexadecane-(1-^^C) (Radiochemical Centre, 
Amersham).
Samples were prepared by various methods to obtain a 
homogenous solution suitable for counting according to 
the following scheme :-
(1) Urine was diluted to a convenient volume with 
water and sub-samples mixed with NE250 (Nuclear Enterprises 
Ltd.,'Edinburgh).
(2) Faeces were dried in vacuo and the dried matter 
pulverised in a small bench mill (Glen Creston Ltd., Slough) 
Sub-samples were combusted in oxygen in a combustion apparatus 
(Packard 302 Sample Oxidizer), and mixed with "Permafluor" 
(Packard Ltd., U.S.A.).
(3 ) Carcasses were skinned and the fur digested in 
2M alcoholic KOH (60 ml per 100 g) under reflux for two 
hours, then made up to convenient volume with water.
The remaining carcasses were chopped up with a meat cleaver 
and homogenised in iced water (2 volumes) in an Atomix 
(MSE). Sub-samples of the slurry were dissolved in 
perchloric acid (l.O ml) and decolorised with 20 volume 
HgOg (0.25 ml). Solutions resulting from digests of, 
fur and carcass were mixed with Emulsion Cocktail T (Fisons 
Ltd., Loughborough) or were combusted and mixed with 
"Permafluor".
(4) Sub-samples from COg trapping fluid were mixed 
directly with 2.0 ml methanol and then with NE260.
(5 ) Washings were made up to volume and a sub-sample 
mixed with NE26O.
(ii) Thin-layer chromatography
Plastic backed plates of silica gel 
(250 nm) impregnated with fluorescent indicator 
were used for all thin-layer work,Polygram SIL G/UV^^^
(Camlab Ltd., Cambridge) gave satisfactory results, with 
ethyl acetate/diethyl ether/acetic acid (glacial) (5:5:1, 
by volume), chloroform/acetic acid (glacial) (l:l, v/v) 
or isopropanol/ammonia solution (sp, gr. 0.88).(lO:l, 
v/v) as the developing solvents. Standard compounds 
developed simultaneously with each sample were all available
from May & Baker Ltd. (see Appendix 3) and included asulam 
(methyl 4-aminobonzenesulphonylcarbainate) (a), N^-acetyl- 
asulam (methyl 4-aoetamidobenzenesulphonylcarbaraate) (b), 
N^-acetylsulphanilamide (4-aoetamidobenzenesulphonamide) 
(C), sulphanilamide (4-aminobenzenesulphonamide (d) and 
2-hydroxyasulam (methyl 2-hydroxy,4-aminobenzenesulphonyl- 
carbamate) (e).
Ref. Compound Name Structure
A Methyl 4-aminobenzene 
sulphonylcarbamate
Asulam HgN^BOg-NHCOOCH^
B ■ Methyl 4-acetamido 
benzenesulphonylcarbamate
4
N -acetylasulam C H ^ C O H N - ^ -  SO^-NHCOOCH
C 4-acetamidobenzene 
sulphonamide
L
N -acetyl­
sulphanilamide
CH^ C O H N - ^ -  SOg-MHg
D 4-aminobenzene
sulphonamide
Sulphanilamide HgNQ^SO^-NHg
E Methyl 2-hydroxy ,4-amino 
benzenesulphonylcarbamate
2-hydroxyasulam HgN<Q-SOg-NHCOOCH^
OH
Solutions suitable for chromatographic analysis were 
prepared by the following methods:-
(1 ) Metabolites in urine were either analysed directly 
on thin-layer plates or were extracted into organic solvent 
at pH3 » Urine was shaken with three equal volumes of 
ethyl acetate (M&B Analytical grade). The organic fractions 
were bulked made to volume a sub-sample evaporated down
to dryness under reduced pressure at 40°C and dissolved 
in 0.2 ml methanol. (For recoveries of asulam, N^- 
acetylasulam and N^-acetylsulphanilamide see Appendix 4),
(2) Metabolites in faeces were extracted in dilute 
base and organic solvent. The dried sample was mixed
with O.IM NaOH (10 ml/g) and agitated for 5nun in an MSE . .
homogeniser. The soluble fraction was obtained after 
initial removal of solid residue by centrifugation (10000 g 
for 15 m)and subsequent removal of heavy colloidal material 
by precipitation with acetone (2 volumes) and 
further centrifugation. Metabolites in the soluble 
fraction were then transfered into ethyl acetate by 
evaporation of acetone and extraction of the remaining 
aqueous sample with three successive equal volumes of solvent 
at pH3.
The removal of metabolites which remained persistently 
bound to the residual faecal material was attempted by 
continuous extraction with solvent. The total residue 
remaining from above was transferred to an extraction thimble 
(Whatman Ltd.) and was extracted continuously for an hour 
with hot methanol in a Soxhlet extractor. Metabolites 
thus obtained were bulked with the ethyl acetate fraction 
and finally a sub-sample evaporated to dryness under 
reduced pressure at 40°C and dissolved in 0.2 ml methanol, 
(For recoveries of asulam see Appendix 4).
Samples in methanol were applied to plates with a 
micropipette (Microcap-Drummond Scientific Co., U.S.A.) 
and development continued to a point 10 cm from the 
origin. Visualization of standards was achieved by 
viewing in ultra-violet light (Hanovia Ltd., Slough) 
while areas of radioactivity were located by scanning 
the radiochromatograms with a Tracerlab 4IT scanner.
3» Results
Overall recoveries of radioactivity in each experiment 
are summarised in Tables 1, 2 and 3, results being expressed 
as percentage of total dose administered contained in each
fraction analysed and summarized as the mean values for 
the appropriate number of replicate experiments.
The amounts of specified metabolites recovered from 
urine or faeces are given in Tables 4, 5, 6 and 7. 
Identification is based on thin-layer chromatography of 
raw urine or organic extracts of urine, with quantification 
made by measuring the areas under the peaks on the various 
radiochromatogram scans. Results from experiments in 
which organic extracts of urine were chromatographed have 
been corrected for recovery of asulam, N^-acetylasulam 
and N^-acetylsulphanilamide and have therefore been 
rendered compatible with additional experiments in which 
raw urine was spotted directly onto plates. Individual 
results for all experiments and thin-layer radiochromato­
gram traces are given in Appendix 5»
TABLE 1 Disposition of radioactivity following a single
dose of C-asulam to rats
(a) oral administration
Rats were given a single oral dose of 10 mg/kg asulam- 
(ring and excreta collected for 24 hours. Results
are the mean values for 6 males and 6 females.
Body Dose
(mg/kg)
Percentage of dose
Sex Weight
(g) Urine Fa eces
Ex­
haled
Air
Car­
cass
Wash­
ings Total
(T 185 9.68 80.9 7.4 <0.02 4.4 3.8 96.5
Î 184 9.57 72.3 5.7 <0.02 8.7 4.0 90.7
TABLE 2 Disposition of radioactivity following a single 
dose of C-asulam to rats
(b) oral administration with biliary cannulation
Cannulated rats were given a single oral dose of 10
mg/kg asulam-(ring ^^C^ and excreta and bile collected for
24 hours. Results are the mean values for 4 males and 4
females.
Body Dose
(mg/kg)
Volume
of
Bile
(ml)
Percentage of dose
Sex Weight
(g) Bile Urine Faeces
Ex­
haled
Air
Car­
cass
Wash­
ings Total
205 9.13 11.6 0.2 57.9 3.3 - 27.7 - 89.1
? 185 9.13 11.8 0.3 72.6 1.8 - 11.7 - 86.1
TABLE 3 Disposition of radioactivity following a single
dose of C-asulam to rats
(c) intravenous administration (metabolism in the gut)
Rats were given a single intravenous dose of 10 mg/kg 
asulam-^ing ^^C^ and excreta collected for Zh hours. Results 
are mean values for 3 males and 3 females.
Sex
Body
Weight
(s)
Dose
Percentage of dose '
(mg/kg)
Urine Fa eces
Ex­
haled
Air
Car­
cass
Wash­
ings Total
1? 192 9.72 99.7 1.2 <0.02 3.2 0.7 104.8
¥ 182 10,26 97.9 0.3 <0.02 1.7 0.5
100.4
TABLE h Chromatography of metabolites in urine from rats
closed with C-asulam
Rats were given a single oral dose of 10 mg/kg asulam»- 
(ring c) and urine collected for 24 hours. Separation 
of metabolites was achieved on thin-layer plates developed 
.in ethyl acetate/diethyl ether/acetic acid(glacial) (5:5:1, 
by volume), isopropanol/ammonia soln. (SG 0.88) (10:1, v/v) 
or chloroform/acetic acid (glacial) (1:1 v/v). Results 
are mean values for 5 males and 4 females (see Appendix).
Sex
Metabolites in urine (^ dose)
HgN-Q^OgNHCOgCH^ c h ^c o n h - Q - s o ^n h c o ^c h ^ CH^COHN-Q-SOgNHg
61 12 2.6
¥ 68
7.8 1.3
TABLE 5 Chromatography of metabolitg^ in urine frotn
cannulated rats dosed with C-asulam
Biliary cannulated rats were given a single oral dose 
of 10 mg/lcg asulam-(ring ^^C) and urine collected for 24 
hours. Separation of metabolites was achieved on thin- 
layer plates developed in ethyl acetate/diethyl ether/acetic 
acid(glacial) (5:5:1, by volume) or isopropanol/ammonia 
solution (SG 0.88) (lO;l, v/v). Results are mean values 
for 4 males and 4 females (see Appendix),
Metabolites in urine (^ dose)
^2 "^0 “ SOgNHCOgCH^ C H ^ C O H N - ^  SOg-NHCOgCH^ CH^COHN-^J)- SOgNH^
24 14 1.0
¥ 40 8.7 0.4
TABLE 6 Chromatography of metabolj-jes in urine from rats 
dosed intravenously with C-asulam
Rats were given a single intravenous dose of 10 mg/kg 
asulam-(ring c) and urine collected for 24 hours.
Separation of metabolites was achieved on thin-layer plates 
developed in ethyl acetate/diethyl ether/acetic acid(glacial) 
(5:5:1, by volume). Results are mean values for 3 males and 
3 females (see Appendix).
Metabolites in urine (^ dose)
Sex
CH^COHN-^-SO^NHCOgCH^ CH^COHN-^ySOgNIi
65 14 0.1
? 74 9.9 0.3
TABLE 7 Chromatography of metabolites in faeces from rats
dosed with C-asulam
Rats were given a single oral dose of 10 mg/kg asulam- 
(ring ^^C) and faeces collected for Zh hours and dried 
in vacuo for a further 15 hours, . Metabolites were 
extracted (i) firstly by homogenising the powdered dried 
material with O.IM NaOH, removing the residue by centrifugation, 
and transfering metabolites from the clear supernatant 
to ethyl acetate by three successive extractions at pH3.
(ii) secondly by perfusing the remaining solid residue 
with hot methanol in a Soxhlet continuous extractor for 
an hour.
Metabolites in the combined extracts were chromato­
graphed on thin-layer plates in ethyl acetate/diethyl ether/ 
acetic acid(glacial) (5 :5 :1 , by volume) or isopropanol/ 
ammonia solution (SG 0.88) (lO:1, v/v). Results are the
mean values for 4 males (see Appendix 5)«
Metabolites in faeces (^ radioactivity in sample)
Recovery
H^NHg-SO^-
NHCOgCH^
CH^COHNH^-
SOgNHCOgCH.^
CH^COHN-Q- Unidentified 
peaks (2 )'*'
(^)
i
i
23.5 47.7 ■2.1 13.1 86.5 1
‘‘one peak had R^.73 in EtOAc/ether/HAC (5:5 si), 8 ,6^ 
at origin
Summary of results
The experiments using a single oral dose essentially 
confirmed results obtained in previous studies, that is:g^.
(a) most of the dose is eliminated in the urine, relatively 
rapidly, 85.-90^ being excreted in a 2k hour period after 
dosing
(b) none of the radiolabelled appears as carbon
dioxide in the exhaled air
(c) the majority of the dose is eliminated unchanged in the
h kurine but N -acetylasulam and N -acetylsulphanilamide
also appear in small amounts representing never more than 15^ 
of the dose.
A more extensive analysis of the metabolic pattern in 
urine, faeces and bile reveals the following additional 
information:-
(a) male rats excrete more acetylated metabolites in urine
(14.7-20^ S.D.) than female rats (9.3±19# S.D.)
/ \ 4(b) much lower levels of N -acetylsulphanilamide are produced 
in the urine of intravenously dosed rats {<0 .3^ dose) than
, in orally dosed rats (up to 2 .6^ dose)
(c) elimination of total metabolites from bile-duct cann­
ulated rats, into the bile is low (0 .3^ dose.in 24 hours)
(d) an 86.5^ extract of unabsorbed material from faeces 
contains higher levels of acetylated metabolites (3 « 9^ 
dose) than can be accounted for by biliary elimination 
alone.
CHAPTER 3
ENZYME INDUCTION STUDIES IN THE WHOLE ANIMAL
1. Introduction
Studies on the metabolism of asulam in animals have 
shown that the compound is resistant in part to extensive 
metabolism and is excreted mostly unchanged. When given 
a single oral dose, only 15^ is metabolised in rats 
(Heijbroek, 1972) most of the remaining drug passing rapidly 
into the urine. This lack of metabolic activity in the 
rat may in part be due to repressed enzyme activity and 
a fuller response by the animal may be afforded by challenging 
with repeated doses of asulam over a period of several 
days, a condition which would simulate the true fate of the 
drug during toxicologioal testing.
Repeated dosage studies have demonstrated that asulam 
does not lead to increased resistance to sulphonamides' in 
young calves (Griffin, Ball & Twitchet, 1975) nor leads to increased 
residues in tissues (Heijbroek, 1972) or milk (Unsworth,
1975)• The effect of repeated dosage of asulam on metabolism 
of asulam has not as yet been carried out.
The metabolism of the common sedative drug phénobarbital 
is stimulated by increased dosing of the drug so that 
actual levels of drug metabolising enzymes in the liver 
are increased (Gillette, 1971) and thus larger proportions 
of drug are converted to Inactive metabolite. This 
phenomenon has been called enzyme induction and the use of 
phénobarbital and also other agents which stimulate their 
own metabolism is common (Remmer, 1972). The possibility 
exists that asulam when repeatedly dosed to animals could 
cause enzyme induction which would take the form of increased 
activity of acetyltransferase and possibly additional 
hydroxylation.
2 « Experimental Section
(a) ^^C-asulam, dosing, animal housing, collection 
and analysis of samples
Procedures followed were essentially those used in 
the previous chapter. The purity of asulam-(ring 
batch DWA 2613B was 99*7^ established by thin-layer chrom-
. xk \
atography as previously described, Asulam-(ring C ) 
batch DUA 2572 if as administered in place of batch DVA 26I3B 
in pre-dosing experiments GM3 and GF3 only.
The original specific activity of batch DVA 2572 was 
20.42 mCi/mM. Purity was measured at 98.6^^ by reverse 
isotope dilution and confirmed by thin-layer chromatography 
using silica gel thin-layer plates (Polygram SIL )
with development in ethyl acetate/methylene chloride 
(40{60, v/v). Solutions suitable for dosing were prepared 
by diluting with cold asulam (batch LOP 2212) to give a 
dosing solution of specific activity 9*29 yiCi/mg.
Rats were housed in cages for long periods of pre­
dosing with unlabelled asulam, the drug being administered 
in the drihlcing water (0.4 mg/ml). Experiments involving 
8 , 70 and 510 days pre-dosing were carried out. In each 
case, a single hot dose of asulam-(ring ^^C) was administered 
the day after cessation of pre-dosing and excreta and ex­
haled air collected for a further period of 24 hours, as 
described in the previous chapter.
(b) Stability Studies
Urine (10 ml), collected for 24 hours after dosing 
with asulam-(ring ^^c) which had been exhaustively 
extracted with ethyl acetate was mixed with 5^ mercuric 
chloride solution (1 ml). Portions of urine (1 ml)
containing the bacteriostatic agent were pipetted into 
test tubes,which were held for 4o hours under different 
conditions of pH and temperature. Buffer (0,5 ml) /Ô.5M 
sodium acetate/HCl pH3; 0.5M sodium acetate/acetic acid pH5; 
0.5M potassium dihydrogen phosphate/NaOH pH?7 was added 
and incubation carried out at 37*^ Ci Incubation mixtures 
were examined by thin-layer chromatography,
(c ) Reverse Isotope Dilution
A methanolic solution of metabolites from urine (O.l ml) 
free from asulam (diagram 2 ) and containing approximately 
20,000 dpm, was added to a solution of N -acetyJsulphanil- 
amide (0.2 g) in water (6 ml), and the solution evaporated 
to dryness under reduced pressure at 40°C. The solid 
obtained was recrystallized from water and a small portion 
(10 mg) dissolved in methanol and NE 270 scintillation 
mixture (Nuclear Enterprises Ltd., Edinburgh) and counted. 
After three recrystallisations a small portion (2 mg) was 
dissolved in methanol and developed by thin-layer 
chromatography ('Uniplate'; 20 x 20 cm; Anachem Ltd.,) in 
chloroform/acetic acid (glacial) (isl, v/v). Visualization 
of N^-acetylsulphanilamxde was achieved in ultra-violet 
light and the radioactivity located by counting 1 cm bands of 
silica substrate in NE 270 scintillation mixture.
(d) Mass Spectrometry '
(i) Separation of metabolites
Urine from rats dosed orally with asulam was adjusted 
to pH3 with 2M HCl and extracted with ethyl acetate. The 
extract was evaporated under reduced pressure and the 
residue dissolved in a small volume of methanol (Pronalys 
grade. May & Baker Ltd.). Samples were submitted to thin-
DIAGRAM 2
Scheme for separation of asulam and metabolites
Urine was obtained from rats dosed orally at lOmg/kg with 
asulam-(ring^ ), Metabolites were obtained after preparative 
thin-layer chromatography of the ethyl acetate extract (pH 5)* in 
ethyl acetate/diethyl ether/acetic acid (glacial) (5:5:1i by vol), 
Compounds were desorbed in water and then extracted into ethyl 
acetate (pH 5),
Urine
Extraction 
EtcAC, pH5
Aqueous residue 
(discard)
EtOAc Extract
Preparative tic
Peak a(Metabolites) Peak b (Asulam) 
(discard)
Desorbtion
then
Extraction 
EtOAC, pH3
EtOAC extract 
( A c e c y l s u l p h a n i l a m i d e j
Aqueous residue 
(discard)
layer chromatography on solvent washed plates (Uniplate;
20 X 20 cm pre-scored; Anachem Ltd., Luton) containing a 
silica substrate (250 nm) with chloroform/acetic acid 
(glacial) (l; 1, v/v) to a distance of 7 cm. The plate was 
then redeveloped in ethyl acetate/diethyl ether/acetic acid 
(glacial) (5:5:1, by volume). Metabolites were located 
by scanning a 5 x 20 cm portion of the chromatogram and
4 4bands corresponding to asulam, N -acetylasulam • and N -
acetylsulphanilamide were scraped away from the plate.
Re-elution of metabolites was begun immediately by 
firstly transfering silica gel containing the absorbed 
metabolites into a clean Pasteur pipette containing a 
washed glass wool plug. The silica was compacted down 
into the pipette by pressing a small plug of glass wool 
on top of the dry silica. Small portions of methanol 
(Pronalys grade, May & Baker Ltd.) were allowed to percolate 
through the dry column. Quantitative recovery of all 
compounds was obtained.
(ii) Clean up
Solutions of the isolated metabolites were taken down 
to dryness under reduced pressure and dissolved in methanol. 
Clean-up was effected on washed thin-layer chromatography 
plates by two consecutive developments in chloroform/ 
diethyl ether/acetic acid (glacial) (.8 :1 :1 , by volume) 
and dichloroiue thane/diethyl ether (l:l, v/v) to a height 
of 15 cm. Metabolites were scraped away and re-eluted in 
methanol.
Methanolic solutions were then evaporated to dryness 
under reduced pressure. Water (5 ml) and n-hexane (5 ml) 
were added and fatty material extracted by vigorous shaking.
The two layers were allowed to settle in a separating 
funnel and the n-hexane run off and discarded. Any remain­
ing n-hexane was evaporated off in a stream of warm air.
Metabolites were extracted from water by adjusting the 
pH to 2 and partitioning into diethyl ether. After five 
extractions the ethereal extracts were combined, evaporated 
down to low bulk, made up to volume (10 ml) and assayed 
for radioactivity by liquid scintillation counting.
(iii) Measurement of spectra
Samples of metabolites (lOXl) were evaporated into a 
glass probe tip and several mass spectra run on a medium 
resolution mass spectrometer (v.G, Micromass 12B), at different 
probe temperatures.
The mass spectrum of N -acetylsulphanilamide was
unobtainable from the sample of metabolite available, but
a spectrum of N -acetylsulphanilamide was obtained at
4
higher temperatures from a sample of N -acetylasulam 
3• Results
Repeated dosage of asulam to rats has been tested in 
short (Table l), medium (Table 2) and long term studies 
(Table 3)» results being given as total recoveries of the 
administered dose. • Results for individual animals are 
given in Appendix 6.
The nature of metabolites in the fraction containing 
largest amounts of administered dose are given (Tables 4,
5 and 6) with results for individual animals with values 
for metabolites in organic extracts of urine corrected for 
recovery.
In addition, amounts of asulam in faeces are given 
(Table 7) but more extensive studies were not followed up
after consideration that recovery of asulam from samples 
and spiked faeces was low and variable even after continuous 
extraction.
Detailed analytical data are given in Appendix 6,
The stability of a polar metabolite in urine was 
tested at different pH (Table 8 and Appendix 9).
The identification of metabolites was based on thin- 
layer chromatography but additionally mass spectrometry was 
used to confirm the presence of a major metabolite, 
acetylasulam in urine from dosed animals (Table 9 and 
Appendix 10).
Data for reverse isotope dilution analysis are given 
in Appendix 12.
TABLE 1 Disposition of radioactivity following a single
dose of C-asulam to induced rats
(a) 8 day induction period
Rats were dosed ab libitum with cold asulam in the
drinking water for 8 days. Medication was then ceased for
24 hours before they were given a single oral dose of
10 rag/kg asulam-(ring and excreta collected for a
further 24 hours. Results are expressed as the mean for
5 males and 5 females.
In­
duction Sex
Body
Weight
(g)
Dose
Percentage of dose
period 
(days)
(mg/kg)
Urine Faeces
Ex- 
ha led 
Air
Car­
cass
Wash­
ings Total
8 214 9.73 69.4 7.2 <0.02 4.5 3.5 84.6
8 Î 216 9.55 73.7 10.5 <0.02 3.4 5.2
92.8
TABLE 2 Dispositjgn of radioactivity following a single
dose of C—asulam to induced rats
(b) 70 day induction period
Single-sex groups of rats were dosed ab libitum with cold
asulam in the drinking water for 70 days. Medication was then
ceased for 24 hours before they were given a single
oral dose of 10 mg/kg asulam-(ring and their excreta
collected for a further 24 hours. Results are expressed
as the mean for 3 males and 3 females.
In­
duction Sex
Body
Weight
(e)
Dose
Percentage of dose
period
(days)
(mg/kg)
Urine Fa eces
Ex­
haled
Air
Car­
cass
Wash­
ings Total
70 456 9.36 85.1 0.85 <0.02 - 0.48 86.5
70 Î 293 8.81 78.3
2.42 <0.02 - 1.04 81.7
TABLE 3 Disposition of radioactivity following a single
dose of C-asulam to induced rats
(c) Life-time study
Single-sex groups of rats were dosed ab libitum with
cold asulam in the drinking water for 1? months. Medication
was thencceased for 24 hours before they were given
a single oral dose of 10 mg/kg asulam-(ring ^^c) and their
excreta collected for a further 24 hours. Results are for
individual animals only.
In­
duction Q A V
Body
Weight
(e)
Dose
Percentage of dose
period
(days)
(mg/kg)
Urine Faeces
Ex­
haled
Air
Car­
cass
Wash­
ings Total
510 600 9.57 89.8 5.1 <0.02 3.1 2.1 100.0
510 Î 495 9.56 81.4 10.8 <0.02 3.7 2.2 98.1
TABLE 4 Chromatography of metabolites in urine from
induced rats dosed with C-asulam
Rats were induced for 8 days then given a single oral 
dose of 10 mg/kg asulam-(ring ^^c) and urine collected for 
24 hours. Separation of metabolites was achieved on thin- 
layer plates developed in ethyl acetate/diethyl ether/acetic 
acid (glacial) (5:5:1, by volume), isopropanol/collidine 
(lO;l, v/v) or chloroform/acetic acid (glacial) (l:l, v/v). 
Results are mean values for 4 males and 4 females.
In­
duction
Metabolites in urine dose )
period
(days)
A
SOgNHCOgCR
C H ^ C O H N - ^ -
SOgNHCO^CH.
C H ^ C O H N -^ ^ S O g N H g
8 a 49.6 12.2 1.8
8
Î 63.3 10.7 3.1
TABLE 5 Chromatography of metabolites in urine from
induced rats dosed with C-asulam
Rats were induced for 70 days then given a single 
oral dose of 10 mg/kg asulam-(ring ^^C) and urine 
collected for 24 hours. Separation of metabolites was 
achieved on thin-layer plates developed in ethyl acetate/ 
diethyl ether/acetic acid (glacial) (5 :$:1 , by volume) 
or isopropanol/amrnonia solution (SG 0.88) (lO:l, v/v). 
Results are mean values for 2 males and 2 females.
In­
duction Sex
Metabolites in urine (^ dose)
period
(days)
SOgNHCOgCHg
C H ^ C O H N .^ ^
SOgNHCOgCH^
C H ^ C O H N - Q ^  SOgNHg
70 66.8 10.5 1.6
70 Î 63.0 12.7 0.5
TABLE 6 Chromatography of metabolites in urine from
induced rats dosed with C-asulam
Rats were induced for a life-time then given a single 
oral dose of 10 mg/kg asulam-(ring ^^C) and urine collected 
for 24 hours. Separation of metabolites was achieved on 
thin-layer plates developed in ethyl acetate/diethyl ether/ 
acetic acid (glacial) (5:5:1, by volume) or chloroform/ 
acetic acid (glacial) (l:l, v/v). Results are given for 
individual animals only.
In­
duction
Metabolites in urine (^ dose )
SexPeriod
(days)
C H ^C O H N -Q - C H ^ C O H N -* ^  SOgNHg
SOgNHCOgCHj SOgNHCOgCHg
510 77.9 8.9 1.8
510 Î 72.0 7.2 1.1
TABLE 7 Chromatography of metabolites in faeces from
induced rats dosed with C-asulam
Rats were induced for a life-time then given a single 
oral dose of 10 mg/kg asulam-(ring ^^C) and faeces collected 
for 24 hours. Preparation of metabolites for chromatography 
was achieved firstly by homogenising the raw faeces with
O.IM NaOH, readjusting the pH to 3 and precipitating the 
insoluble residue with acetone and a few drops of saturated 
aluminium sulphate solution, then removing the acetone under 
reduced pressure, and extracting the purified concentrate 
with ethyl acetate. Metabolites were separated on thin- 
layer plates developed in ethyl acetate/diethyl ether/acetic 
acid (glacial) (5:5:1, by volume) or chloroform/acetic 
(glacial) (1:1, v/v). Results are given for individual 
animals only.
Induction
period
(days)
Sex Unchanged drug in raw faeces (^ dose)
510
510
S'
Ï
1.6
7.6
TABLE 8 Formation of asulam from an unidentified
conjugate in urine from rats dosed with
C-asulam
Rats were dosed intravenously with 10 mg/kg asulam- 
(ring ^^C) and their urine collected for 24 hours. The 
urine was adjusted to pH3 and extracted five times with 
equal volumes ethyl acetate and split into six samples. 
pH was adjusted to 3, 5» 7 or 9 with appropriate buffer 
(0.5M) and mercuric chloride added to 1^. The samples 
were then held for 40 hours at 37^C (or 4°c), formation 
of asulam being followed by thin-layer chromatography in 
ethyl acetate/diethyl ether/acetic acid (glacial) (5:5:1, 
by volume). Results are single determinations for each 
value of pH. Further data and radiochromatogram traces 
are given in Appendix 9.
pH
Yield of asulam 
after 4o hours
(^)
3 73.6
5 72.4
7 4.6
9 8 2 .8"*'
held at 4°C
TABLE 9 Structural confirmation of a motobolite by mass
spectrometry
Rats were given drinking water containing asulam at 
0,4 mg/ml for 8 days, followed by a single oral dose at 
10 mg/kg of asulam-(ring . Urine was collected, extracted
with ethyl acetate (pH3) and metabolites isolated by 
preparative thin-layer chromatography on silica in 
chloroform/acetic acid (glacial) (l;l, v/v). The re-eluted 
material was cleaned by further thin-layer chromatography 
on silica in chloroform/diethyl ether/acetic acid (glacial) 
(8:1:1, by volume). Finally the metabolite was extracted 
into ether (pH3) and mass spectra run at 150°C (N^- 
acetylasulam) and 260°C (N^-acetylsulphanilamide) (Figure 
B Appendix lO) . Major fragment ions common only to both 
sample and standard are listed below.
Peak
(M/e) Fragment Ion Intensity
272 CH^COHN-Q^ SOgNHCOgCH^lt weak
240 CH^COHN-Q- S02-N=C=0lt medium
198 strong
151 CH^COHN-^- Oh IÎ weak
135 CH^COHM-^ IT weak
Summary of results
Average values for excretion of total acetylated species 
in urine following induction are as follows
(a) after 8 days induction, l6 .6^ found in males and 
13«0^ in females (4 animals studied).
(b) after 70 days induction, 12.6^ found in males and 
13.5^ in females (2 animals studied),
(c) after 510 days induction, 10.7/o found in male, and 
8 ,3^ in female (l animal studied).
Levels of polar metabolites found in urine, were 2,0^ 
in both males and females.
4 4The structure of N -acetylasulam and N -acetylsulphanil­
amide has been confirmed by mass spectrometry and reverse 
isotope dilution respectively. .......
CHAPTER 4
PENETRATION OF ASULAM TO THE SITES OF METABOLISM
1. Introduction
The major organ of metabolism in mammals is the liver. 
Most absorbed food and also foreign compounds firstly pass 
through the liver via the hepatic portal vein, so that 
metabolism and detoxification can take place.
The isolated liver, if maintained in a viable and 
metabolically active state, can be a useful tool with which 
to study the metabolism of compounds which are poorly absorbed 
or only partially metabolised in vivo. By the technique 
of liver perfusion (Miller, Ely, Watson and Bale, 1951;
Brauer, Pessotti and Pizzolato, I951) the liver can be exposed 
to drugs and foreign compounds for a greatly extended 
period and thus enable the ultimate metabolic fate of 
compounds to be studied.
Asulam is only poorly metabolised in vivo (circa 12^)
4 4
to N -acetylasulam and N -acetylsulphanilamide, the majority 
of drug (circa 705®) being eliminated unchanged. Reports 
on the existence of 3-hydroxysulphanilamide which is an 
hydroxylated metabolite of sulphanilamide (X) (Dobson 
and Williams, 1946; Williams, 1947) a compound with structural 
similarity to asulam, posed the problems of whether asulam
(X)
could be metabolised by ring hydroxylation and whether this 
type of metabolism could be induced experimentally using 
the perfused liver, so that larger amounts of the hydroxy 
asulams would be obtained.
Asulam is rapidly eliminated from the rat after a
single oral dose (circa 90^ in 24 hours) and consequently 
levels of drug in blood are never high enough for long-term 
exposure to the liver in vivo. Study of the fate of asulam 
using the perfused rat liver may therefore show whether the 
absence of hydroxylated metabolites and low level of metabolism 
apparent in vivo, is a consequence of rapid elimination of 
asulam from blood,
2. Experimental Section '— -
(a) Chemicals
l4Asulain-(ring C ) (99^ pure; 11.4 /iCi/mg) was dissolved 
in a stoichiometric amount of M NaOH and made up to 40 mM 
(0.10/iCi/ul) with 0 .9^ saline. N -acetylasulam, N - 
acetylsulphanilamide and sulphanilamide were all available 
from May & Baker Ltd., Dagenham, Essex.
(b) Perfusion medium
A medium comprised of 100 ml of tissue culture medium 
199 without phenol red (Difco Laboratories, Detroit, Michigan, 
U.S.A.), 2,5 g bovine serum albumin fraction X  (Sigma Chemical 
Company, St. Louis, Missouri, U.S.A.), 500 units heparin 
(BDH Chemicals Limited, Poole, Dorset) and 75 mg gentamycin 
(Plow Laboratories Limited, Irvine, Ayrshire) was prepared 
and 65 ml of this medium made up to 100 ml with goat 
erythrocytes (washed twice with isotonic saline) to give 
the perfusion medium. The remaining cell free medium 
(35 ml) was used as the pre-perfusion medium.
(c) Animals
An adult female Swiss Alpine goat was used as the donor 
of red blood cells and male Wistar albino rats (220-250 g) 
as the liver donors. All animals were allowed food and 
drink ad libitum before experiments.
(d) Perfusion technique
Rats wore anaesthetized with sodium pentobarbitone 
(Nembutal, 60.mg/kg) and the bile duct and hepatic portal 
vein of each cannulated with pp25 and pp60 polypropylene 
tubing (Portex Ltd., Hythe, Kent) respectively. An in situ 
infusion of the liver with the pre-perfusion medium (10 ml/ 
min) was performed during hepatectomy after which the liver 
was connected into a perfusion system similar to that 
described by Curtis, Powell and Stone (I97O). In this 
system the medium was oxygenated by a continuous stream of 
a moistened mixture of 95^ 0^ and 5^ CO^ passing over a 
multibulb oxygenator,
The liver was then perfused at a rate of 1 ml/min/g 
liver under a constant hydrostatic pressure of 30 cm per­
fusate at 37°C and the system allowed to equilibrate for 
30 minutes before the addition of the substrate (psulam,
9 mg, 17.2 yUCi). Perfusate samples (0.25 ml) were collected 
from sampling ports before and after the liver at various 
time intervals during the perfusion and bile collected at 
half-hourly intervals in pre-weighed LP3 plastic tubes 
(Luckham Limited, Burgess Hill, Sussex).
(e) Radiochemical methods
Samples deriving from plasma and bile were mixed with 
dioxane based scintillator (NE25O Nuclear Enterprises 
Limited, Edinburgh, Scotland) while those deriving from 
whole perfusate and liver homogenates were either digested 
and decolourised then mixed with triton/toluene scintillator 
(Emulsion Cocktail T, Fisons Limited, Luton, Bedfordshire), 
or were prepared for counting with a Packard 302 Sample 
Oxidiser utilizing a 10:12 mixture of ^ fcarbosorb” and
PLATE 2
LIVER PERFUSION STUDIES
PERFUSION SYSTEM (AFTER CURTIS, POUELL AND STONE. 1970)
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&
KEY TO PLATE 2 
LIVER PERFUSION APPARATUS 
A - Constant head device 
B - Multibulb oxygenator 
C - Thermometer/Thermostat 
D.E - Heaters 
F - Heat exchanger 
G - Peristaltic pump 
H - Filter 
I - Reservoir 
J - Liver
K - Biliary cannula 
L - Flow adjustment tap 
M - water bath 
N - Oxygen supply 
0 - Magnetic stirrer
P,Q - Perfusate sampling ports (before and after liver) 
R - Humidifier for oxygen supply
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Permafluor (Packard) respectively. All samples were counted 
on a Tracerlab Corumatic 200 Spectrometer, standardization 
being achieved by the internal method using hexadecane 
(l-^^C) (Radiochemical Centre, Amersham, Bucks).
Tissues and fluids were treated as follows
(i) Whole blood (0.25 ml) was either centrifuged 
on a Beckman Microfuge to sediment erthrocytes and samples 
of plasma (lOX 1) mixed with scintillator (20 ml) and 
counted or digested with Protosol (l.O ml) (New England 
Nuclear Limited, Boston, Mass., U.S.A.), decolourised with 
benzoyl peroxide (May & Baker Ltd., 0.1 ml of saturated 
solution in toluene) mixed with scintillator (20 ml) and 
counted.
(ii) Bile was diluted with water (l.O ml) and 
samples (0.4 ml) mixed with scintillator (20 ml) and 
counted.
(iii) Livers were washed with 0.9^ saline the 
washings being added to the remaining perfusate and 25# 
aqueous homogenates prepared. Samples (0.2 ml) were 
either digested with tissue solubilizer or were combusted 
and counted.
(f) Extraction procedures
Plasma (10.0 ml) was extracted five times with equal 
volumes of ethyl acetate at pH3. Liver homogenates pre­
pared with water ( 2 ml/g tissue) wer.e shaken with equal 
volumes of ethyl acetate at pH3 and emulsions were broken by 
high speed centrifugation (10000 g for 15 m). Organic 
fractions were made up to volume,samples evaporated to 
dryness under reduced pressure and dissolved in methanol 
(0.2 ml) for examination by t.l.c.
(g) Enzymic hydrolysis
Samples of the aqueous residue (2,0 ml) remaining afÿer 
ethyl acetate extraction were neutralised to pH? with 2M 
KOH then incubated with 25 mg ^ -glucuronidase (Type HI, ex 
Helix Pomatia containing some sulphatase and Type B1 ex 
Bovine Liver; Sigma Chemical Company, St. Louis, Missouri, 
U.S.A.) for k hours at 37°C. Portions of the hydrolysate 
were re-extracted with ethyl acetate at pH3. Organic 
extracts were evaporated to dryness under reduced pressure 
at 40°C, dissolved in methanol (0.2 ml) and examined by 
t.l.c.
(h) Agueous hydrolysis
The neutralised aqueous residue was hydrolysed as 
described above but without enzyme and in the presence 
of saccharo-1,4-lactone (0.2 mM) to inhibit any enzyme 
activity in the sample. Portions of the hydrolysate were 
analysed as described.
(i ) Chromatographic methods
Separation and identification of metabolites was 
achieved on thin-layers of silica gel (Polygram SIL G/UVg^^^, 
Camlab, Cambridge). For qualitative determination of asulam,
4 4N -acetylasulam and N -acetylsulphanilamide aliquants 
(O.Ol ml) of organic or aqueous samples were chromatographed 
on 5 3C 20 cm sheets in ethyl acetate/diethyl ether/acetic 
acid (glacial) (5 : 5 :1 * by vol.), isopropanol/ammonia soln.
(sp. gr. ,880) (lO:l, v/v), chloroform/acetic acid (glacial) 
(l;l, v/v) chloroform/diethyl ether/acetic acid (glacial) 
(8 :8 :1 , by vol.) toluene/êthanol (l:l, v/v) or nbutanol/
formic acid (98# soln.) (4:1, v/v).
4
In addition, analysis for N -acetylsulphanilamide was
carried out by chromatographing samples on silica gel plates
in ethyl acetate/diethyl ether/acetic acid (glacial) (5 :
5 :1 , by volume), re-eluting in methanol the specific area
4
on the developed plate corresponding ,to the of N - 
acetylsulphanilamide and re-chromatographing the recovered 
material on silica gel plates in isopropanol/ammonia solution 
(S.G. 0 .88) (10:1, v/v).
Developed radiochromatograms were scanned using a 
Tracerlab 4TTscanner; standard compounds were visualized 
under UV light at 254 nm (Hanovia Limited, Slough,
Middlesex).
To obtain quantitative data plasma and bile (10 Xl) 
were spotted onto 20 x 20 cm Polygram sheets (t.l.c.) 
and chromatographed in ethyl acetate/diethyl ether/acetic 
acid (glacial) (5:1:1, by vol.). The developed sheets 
were clamped together with X-Ray sensitive film (llford 
Red Seal) and left in the dark for one week. Autoradio­
grams were developed and used to locate radioactive spots.
The appropriate areas were cut out with scissors, the 
small squares steeped in methanol overnight and finally 
counted in dioxane-based scintillator (NE250) with the 
silica facing upwards.
3* Results
Asulam is not metabolised rapidly by the perfused
rat liver but is taken up rapidly by erythrocytes and
hepatic cells, yet is not eliminated in bile (Figure l).
N^-acetylasulam is obtained in plasma from perfusate along
with several minor metabolites (Plate 3). The kinetics
4
of acétylation of asulam to N -acetylasulam are first 
order in the perfused liver; the volume of distribution
and other coefficients are given in Table 1. Fractionation
of radioactivity as set out in Figure 3 demonstrates that
most of the unchanged drug and major metabolite is present
in the plasma fraction but that small amounts of conjugates 
4
of asulam, N -acetylasulam and other species are also 
present in plasma which can be hydrolysed either in the 
presence (Table 2) or absence (Table 3) o f yÔ-glucuronidase. 
Identification of total metabolites in the fractions 
analysed is presented in Table 4. All analytical data 
including radiochromatogram traces are presented in Appendix 7»
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Recovery of radioactivity after metabolism of '*^ C-asuli='Tn by 
perfused rat liver.
A single viable rat liver (lOg) was perfused with a reconstituted 
medium (lOO ml) (see text) a^^lO ml/m and 37°C. At time 0 a 
single dose of asulam-(ring c ) (9mg, 17y*Ci) was added and 
samples (0.25 ml) of perfusate taken before and after the 
liver. Bile was collected continuously.
FIGURE 2
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Depletion of unchanged drug from plasma after metabolism of 
^^C-asulam “by the perfused rat liver.
A single viable rat liver (10 g) was perfused with a 
reconstituted medium (lOO ml) (see text) at 10 ml^m and 
37 C. At time 0 a single dose of asulam-(ring C )
( 9 mg; 17>UCi) was added to the perfusate and thereafter 
samples of perfusate (0.25 ml) were removed. Perfusate 
sampled after the liver was centrifuged and plasma 
analysed for unchanged drugi
TAB LB 1
Parameters for clearance of C-asulam by the perfused rat 
liver
A single viable rat liver (lO g) was perfused with a . 
reconstituted medium (see text) at 10 ml/m and 37°Ç»
After a single dose of asulam-(ring ^^C) (9 mg) was added 
to the perfusate (lOO ml), samples of plasma taken after 
the liver were analysed for unchanged drug.
Volume of plasma (ml)
-1 \Volume of distribution (ml )
Elimination constant (hr~^) 
Clearance rate (ml ^hr ^g
65
129
0.119
1.34
PLATE 3 - Metabolism of asulam in the perfused liver
Thin-layer chromatography of the perfusate after 6 hours 
perfusion.
Dose;- Sodium asulam-(ring )
Solvent:- Ethyl acetate/ether/acetic acid (5:5:1, by volume)
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TABLE 2
lUEnzyme hydrolysis of plasma following metabolism of C- 
asulam by the perfused rat liver
A single viable rat liver (10 g) was perfused with a 
reconstituted medium (lOO ml) (see text) at 10 ml/m and 
37°C. Asulam~(ring ^^C) was added and perfusion continued 
for 6 hours. Plasma obtained from the perfusate by 
centrifugation was exhaustively extracted with ethyl 
acetate at pH3 then adjusted to pH? and aliquots (2 ml) 
incubated with two types ofyS-glucuronidase enzyme (type 
B1 ex Bovine liver 2?00 units/ml; type HI ex Helix Pomatia 
1370 units /ml) for h hours at 37°C. Products were 
extracted into ethyl acetate and chromatographed on thin- 
layers of silica (23O nra) in ethyl acetate/diethyl ether/ 
acetic acid (glacial) (5:5:1, by volume).
Conditions of 
Hydrolysis
Metabolites in aqueous residue H 
from plasma (^ labelled species)
H„N-fV SO^-NH-
. : L/-
CH-COHN-^'VSO -NH- 
^  tOgCHg
)B-glucuronidase-Bl 
at 2700 units/ml pH? 27.4 17.1
yB-glucuronidase-Hl 
at 1370 units/ml pH? 32.6 14.5
TABLE 3
Aqueous hydrolysis of plasma following metabolism of ^^C- 
asulam by the perfused rat liver
A single viable rat liver (lO g) was perfused with a 
reconstituted medium (lOO ml) (see text) at 10 ml/m and 
37°C. Asulam-(ring was added and perfusion continued
for 6 hours. Plasma obtained from the perfusate by 
centrifugation was exhaustively extracted with ethyl acetate 
at pH3 then adjusted to pH? and an aliquot (2,0 ml) in­
cubated for 4 hours at 3?°C with saccharo-1,4-lactone (0.2 mM) 
to inhibit ^ -glucuronidase activity,
#
Products were extracted into ethyl acetate and chromatographed 
on thin-layers of silica (25O nm) in ethyl acetate/diethyl 
ether/acetic acid (glacial) (5:5:1, by volume).
Conditions of 
hydrolysis
Unidentified hydrolysis products 
from plasma (^ radioactivity 
in extract D from plasma)
Compound A Compound B Origin
pH? with
saccharo-1,4-lactone 2.3 3.1 6,8
TABLE 4
Identification of metabolites in tissues and fluids 
following metabolism of ^^C-asulam by the perfused rat liver 
A single viable rat liver (10 g) was perfused with a 
reconstituted medium (lOO ml) (see text) at 10 ml/m and 
37°C. Asulam-(ring (9 mg; 17/UCi) was added and
after 6 hours perfusion metabolites in perfusate, bile 
and liver were extracted and analysed by thin-layer 
chromatography on silica (250 nm) in ethyl acetate/diethyl 
ether/acetic (glacial) (5:5:1, by vclume) or isopropanol/ 
ammonia soln. (S.G. 0,88) (lO:l, v/v).
Proposed identification
^ radioactivity
Liver Bile Plasma
Asulam 1.0 0.30 21.8
N^-acetylasulam 7.0 0,48 18.2
N^-acetylsulphanilamide - <0.5 <0.8
Asulam conjugate - - 3.0
h
N -acetylasulam conjugate - - 1.4
Unidentified A <0.1 <0.01 0.53
Unidentified B 1.9 <0.01 3.5
Unidentified C (origin) 3.8 0.11 0.47
Recovery 13.7 0.89 49.79
Total 64.38
Summary of results
(a) Asulam is metabolised by the perfused rat 
liver by first order kinetics (elimination constant =
0.119 hr“^),
(b) Elimination of metabolites in the bile is less 
than 1 .0^, the majority of dose being recovered in the 
perfusate.
(c) Asulam is taken up by liver cells and erythrocytes 
(volume of distribution s 129 ml , l4^ of the dose is 
resident in the liver tissue after perfusion for 6 hours.
(d) Asulam is metabolised to N^-acetylasulam (25.7^ 
dose) and not less than 3 minor metabolites (lO^ dose). 
Hydrolysis studies withyB-glucuronidase have been used.to 
verify the identity of the minor metabolites.
(e) Apparently no N -acetylsulphanilamide is produced 
in the perfusate.
CHAPTER 5
INTERACTION OF ASULAM WITH DRUG-^ÎETABOLISING ENZYMES
1. Introduction
A natural extension of the present project is the 
study of the interaction of asulam with the isolated but 
intact liver enzymes, for knowledge of the fate of asulam 
in the in vitro state could be important in showing whether 
asulam can indeed act as substrate to the drug-metabolizing 
enzymes of the liver or whether it is unable to penetrate 
adequately the plasma-cell membranes for entirely kinetic 
reasons.
The interaction of asulam with viable membranes has 
been studied, at a superficial level in the whole animal 
and the perfused liver, Asulam is readily taken up by 
erythrocytes and liver cells during perfusion. High levels 
of asulam in the direct vicinity of the intracellular 
enzymes should lead to efficient metabolism and elimination 
into the extracellular circulating fluids, unless the 
metabolite itself is unfavourably partitioned back into the 
extracellular and extrahepatic space. This may be an 
unlikely situation as metabolism of asulam say to the ring 
hydroxylated product introduces an additional acidic centre 
which would increase the state of ionisation and solubility 
at physiological pH. The inability of asulam to form 
metabolites in sufficiently large amounts in the extra­
cellular fluids, as demonstrated in these experiments, may 
then reflect lack of binding to the actual sites of 
metabolism within the cell.
In consideration of the problem of apparent unreactive- 
ness of asulam in the whole animal and perfused liver it 
was thought desirable to complete these studies by using 
well-established laboratory techniques to observe the
interaction of asulam with drug-metabolising enzymes,
(b) Choice of enzyme preparation and assay
Many drugs have been studied by inducing metabolism 
in vitro in the presence of preparations of hepatic enzymes . 
so that the class of enzyme most commonly used, an NADPH- 
linked cytochrome isolated from the microsomes, is 
commonly held as being the major site of hydroxylation*
In the case of asulam however, previous studies 
have shown a preference for acétylation, a metabolic process 
which is mostly resident in the soluble portion of the 
cell. Thus two types of metabolism can be conveniently 
separated, the hydroxylation of asulam in the microsomes 
and its acétylation in the soluble portion or cytosol.
Selection of enzyme preparations for hydroxylation were 
confined therefore to those fractions containing the micro- • 
somes, while all fractions were tested for acétylation.
The assay for hydroxylated metabolites was based on 
previous studies (Schenkman, Remmer & Estabrook, 196?;
McPherson et al, 1976) but using a modified colorimetric 
reaction between diazqtised sulphanilic acid and phenols 
(Orimmett and Richards, I965), derived from the observation 
that this reagent forms an intense yellow-brown coloration 
with 2-hydroxyasulam on thin-layer plates (Heijbroek, 
unpublished). The yellow produced in solution with 2-hydroxy- 
asulam was also obtained with 2-hydroxysulphanilamide and 
thus was not specific for^ benzenesulphonylcarbamates«
Assay for acetylated metabolites was based on the standard 
method for.N-acetyltransferase (Veber, 1971)*
(c ) Spectral studies
Binding studies have been conducted for many pharm-
aceuticals which are known to be hydroxylated in the body 
(Remmer et al, I966). These have shown that the absorp­
tion spectrum of resuspended microsomes is altered by the 
presence of the binding species which can effect a shift 
of the absorption maximum of cytochrome haem-iron to longer 
wavelengths (type I, e.g. aminopyrine) or to shorter wavelengths 
(type II, e.g. aniline). Reverse type I binding has also 
been reported (Kumalci et al, 1978) which is almost exactly 
a mirror image of type I.
Type II substrates,such as aniline, form a spectral 
maximum at about 427 to 4 30 nm and minimum at about 390 to 
4lO nm (Kumaki et al, 1978) and are suggested as binding 
directly to the haem-iron of cytochrome P 450 (schenkman 
et al, 1967;Schenkman & Sato, 1968),
(d) Electrochemical studies
An electrode containing an oxygen-permeable membrane 
was introduced by Clarke (1956) for the monitoring of 
plasma oxygen levels in heart-lung machines. Modifications 
were later used widely for following hydroxylation reactions 
in vitro (Netter and Kahl, I969; Narasimhulu, 1971)*
Wolf et al, (1975) reported on a gold/silver electrode, 
which was more practical and sensitive than the Clarke-type 
electrode and which could be used for quick and accurate 
determination of the metabolism in vitro of some xenobiotics.
For the purposes of extending the investigation on 
asulam metabolism in vitro, a modification of the Clarke 
electrode made by Reed (I972) was used to determine oxygen 
uptake.
(e) Conclusions
The metabolism of asulam by acétylation and hydroxy-
lation can be studied by a number of techniques using 
preparations of tissue homogenates, and spectroscopic, 
colorimetric and electrochemical methods to follow metabolic 
and binding properties of the compound. In addition radio­
chemical methods can be used to follow the in vitro metabolism 
of ^^C-asulam.
2. Experimental section
The fate of asulam was compared with that of structurally 
similar test compounds, which were also used to give a 
positive criterion for the activity of enzyme preparations 
used in the study.
Sulphanilamide, aniline, sulphamethazine and biphenyl 
were used for incubations; aniline and sulphanilamide were 
tested with asulam for binding to cytochrome P^^O.
(a) Materials
Asulam as the sodium salt In aqueous solution (Batch 
LOP 2212, 995^  pure) was used for all in vitro studies.
Aniline was dissolved in water as the hydrochloride, 
sulphanilamide was dissolved in dilute NaOH, sulphamethazine 
(also known as sulphadimidine) was dissolved in water, amino­
pyrine was used as a dilute solution in acetone, biphenyl
was solubilized by dissolving I85 mg in Tween 80 (2 g).
then diluting to 100 ml with aqueous 1.15^ (w/v)KCl.
Solutions of biphenyl were warmed to dissolve any precipitate 
before use (Creaven, Parke Æ Williams, 1965)..
(b) Preparation of liver cell fractions
Male albino rats 150-200 g of the Sprague-Dawley strain 
were sacrificed by cervical dislocation, their livers removed
and a 25 S portion cooled on ice for 10 minutes. Livers
were then homogenised to 25^ (w/v) with O.IM KHgPOU/NaOH
buffer pH 7*6 (75 ml) in a bench homogeniser (MSE) for 2 
minutes (Fraction l). The primary honiogenate was then 
fractionated • for 20 minutes on an MSB Superseed 50 refrigerated 
centrifuge to produce the 10,000 g sediment and for a 
further 60 minutes to produce the 100,000 g sediment and 
cytosol. Sediments were rehomogenised to give working 
solutions of the appropriate enzyme fraction by the 
following methods:—
Fraction 2 - Mitochondria, nuclei and cell debris 
The 10,000 g sediment was mixed with O.IM KHgPOU/NaOH 
pH 7.6 (15 ml) and homogenised in a Potter-Elvejham homo- 
geniser.
Fraction 3 - Post-mitochondrial supernatant 
The 10,000 g supernatant was decanted into a measuring 
cylinder, made up to 60 ml with buffer, shaken and a 10 ml 
sample obtained.
Fraction 4 - Microsomal supernatant (cytosol)
The 100,000 g supernatant was used directly.
Fraction 5 - Washed microsomes
The 100,000 g sediment was washed with ice-cold 
O.IM KH2P04/Na0H buffer pH 7.6, resuspended by shaking and 
stirring with a glass rod and was then recentrifuged.
The washed pellet was further resuspended by homogenisation 
in buffer (9 ml) in a Potter-Elvejham homogeniser.
(c ) Incubation and analysis of metabolites
(i) Acétylation 
The concentrations of species in the incubation 
mixture were as follows: Tris buffer pH 6.8 , 70 mM; acetyl-
S-CoA, 20 AtM; asulam or test compound, 30 A*M« Solutions 
were made up to 1.0 ml, control tubes containing no co-
strate and continued at 37°C for 15 minutes. The reaction 
was stopped by the addition of 2,0 ml of 5^ trichloracetic 
acid.
After centrifugation of the incubation mixture freshly 
prepared 0.1^ (w/v) sodium nitrite (0,2 ml) was added to 
2,0 ml of supernatant. After 3 minutes excess nitrite 
was removed by shaking with 0,5^ (w/v) ammonium sulphamate 
(0,2 ml). After a further 3 minutes 0,05^ (w/v) N-1- 
(napthyl)-ethylenediamine (l.O ml) was added and finally 
after a further 30 minutes the optical density was measured 
at 540 nm against water,
(ii) Hydroxylation 
The concentrations in the incubation mixture were as 
follows: Tris buffer pH 7*6, 80 mM; MgClg, 20 mM; glucose-
6-phosphate, 25 mM; glucose-6-phosphate dehydrogenase, 2 
units; NADP, 1 mM; asulam or test compound, 5mM, Solutions 
were made up to 1,0 ml and incubated at 37°C for 15 minutes, 
the reaction being started by the addition of 0,1 ml NADP 
and stopped with 2,0 ml 5^ trichloracetic acid. Control 
tubes contained no NADP, The incubation mixtures were 
centrifuged and 2.0 ml samples of the supernatant neutralized 
with M sodium carbonate (2,0 ml). Tubes were analysed for 
products of hydroxylation according to substrate used.
Protein content was determined by the method.of Lowry et 
al (1951).
(1) Asulam and sulphanilamide 
Tubes containing either asulam or sulphanilamide were 
analysed by a colorimetric method involving derivitisation 
with diazotised sulphanilic acid (Grimmett and Richards,
1965). A stock solution of sulphanilic acid (12.5/6 w/v 
in cone HCl) (8.5 ml) was diluted to 50 ml with water in 
a 250 ml conical flask. A freshly prepared solution of 
sodium nitrite (O.l^ w/v) (5 ml) was added drop-wise to 
the ice-cold sulphanilic acid while the flask was shaken 
vigorously. After 15 minutes excess nitrite was removed 
with ammonium sulphamate (0.5^ w/v) (3 ml). After a 
further 3 minutes the diazotised sulphanilic acid or 
coupling mixture was ready for use. A sample (O..I ml) 
of the above mixture was added to the neutralised reaction 
mixture and mixed well. After 15 mins the resulting 
yellow colour was measured at 430 nm against a reagent blank.
This method, devised and developed as an effective 
colorimetric assay for hydroxylated benzenesulphonamides, 
did not obey a linear concentration dependence, i.e. the 
Beer-Lambert law, at low concentrations of hydroxy sulphonamide. 
The absorption spectrum of colored adduct formed at con­
centrations of hydroxy sulphonamide below 60 using the 
above method, showed two peaks at 370 nm (Figure a8/c) and 
430 nm. Absorption from an unknown secondary product, 
also formed in the absence of hydroxysulphonar.ide, interfered 
with assay for the hydroxylated metabolites causing some 
loss of sensitivity in the method especially in the lower 
concentration range (Figures a8/A and a8/B). Subtraction 
of a reagent blank was satisfactory in accounting for 
secondary product formation.
(2) Aniline
The major metabolite of aniline in microsomes, p- 
aminophenol (wills, 1969; Parke, I96O) was analysed by 
formation of a colored complex with phenol.
A sample of phenol (lO^ w/v in 0.5M NnOIl) (O.l ml) 
was added to the neutralised reaction mixture. After a 
15 min development time, the color was read at 4^0 nm®
(3 ) Biphenyl
Estimation of 4-hydroxybiphonyl in the acidified 
reaction mixture was based on the fluorimetric method of 
Creaven, Parke &• Williams (1965).
An aliquot (2.O ml) of original supernatant (without 
addition of sodium carbonate) was extracted with n-heptane 
(10 ml). The two layers were separated by centrifugation 
for 5 minutes and an aliquot (2.0 ml) of the heptane layer 
(upper) was drawn off with a pipette. Metabolite in the 
organic layer was then re-extracted into O.IM NaOH (10.0 
ml) by shaking for 5 minutes. Tho two layers were separated 
by further centrifugation for 10 minutes. The aqueous 
layer containing 4-hydroxybiphonyl, was separated with a 
Pasteur pipette. Assay of metabolite was achieved by 
measuring fluorescence output at 400 nm after excitation 
at 311 nm on a spectrofluorimeter (Zeiss ZFM 4c) fitted 
with a xenon illuminator.
(iii) Hydroxylation of radiolabellod substrate
The metabolism of asulam was further followed using 
asulam containing uniformly-Babelled carbon-l4 in the 
aromatic ring (l).
H 2 N - Æ \ s 02-NHC02CH3
i±)
The incubation procedure was as described earlier. 
Sodium asulam-(rinn~ ^^c) (Batch DWA 2613B; 99*7f6 pure) 
(0,3 mg; 0.043 ^ Ci/uM) was incubated for I5 hours in the
presence of Cvystnmycin (Glaxo Laboratories Ltd., Greonford; 
100 units) to prevent bacterial, growth. An incubation 
with aniline (cold) was used to check for enzyme activity. 
Incubation mixtures wore analysed for radiolabellod 
metabolites by direct examination on thin-layer chromatography 
plates, by examination of tho ethyl acetate extract on 
thin-layer chromatography plates and by mass spectrometry 
and absorption spectroscopy of the re-eluted material 
from plates.
(1) Separation of metabolite
An aliquot (lOywkl) of incubation mixture was spotted 
directly onto the origin of a 5 x 20 cm silica gel plate 
(Polygram SIL . The charged plate was developed
in ethyl acetate/diethyl ether/acetic acid (glacial)
(5:5:1, by volume) for a distance of l4 cm. Radioactivity 
on the plate was detected using a Tracorlab 4*TT radiochromato­
gram scanner.
(2) Transfer of metabolite to organic phase 
The incubation mixture was made up to 10 ml with
water and adjusted to pH 3 with HCl. Unchanged drug and 
metabolite were extracted into ethyl acetate in a 50 ml 
separating funnel. Aliquots (o.l ml) of both fractions 
were assayed for radioactivity in NE260 scintillator.
(3 ) Isolation of metabolite.
A sample of the ethyl acetate fraction (5 ml) was 
evaporated to dryness in a 25 ml round-bottom flask under 
reduced pressure at 37°C. Residual material was 
redissolved in 0.5 ml of methanol and an aliquot (40y*.l) 
applied to the origin of a 5 x 20 cm silica gel plate 
(Merck, Kieselgel 60 Fg^^) by successive spotting and
The charged plate was developed in etliy], acetate/diethyl 
ether/acetic acid (glacial) (5:5:1, by volume), Radio­
activity on the plate was located using a Tracerlab 
radiochronatogram scanner,
A band of silica coincident with the required peak 
of radioactivity was scraped away from the developed plate. 
Metabolite absorbed to silica was re-eluted by shaking with 
two successive portions of methanol (TO ml),
(4) Mass spectrometry of metabolite
. An aliquot of methanol desorbate (l.O ml) was evaporated 
to dryness under a stream of nitrogen. The mass spectrum 
of the sample dissolved in a few drops of methanol was 
recorded at 200^0 (Figure A10/d ), using a V.G* Micromass 12B 
mass spectrometer (scan time 100 sec ; excitation potential ?OeV).
(5) Absorption spectroscopy of metabolite
The final methanol desorbate was subjected to absorption 
spectroscopy on a Cary 17 spectrometer. A sample of 
solution (4 ml) was scanned in the spectral range 3OO-5OO nm 
against methanol (Figure 83).,
(d ) Spectral studies
The binding of asulam to hepatic microsomal cytochromes
*
(Remmer et al, I966) was compared with that of sulphanilamide 
and aniline by the method of Cox, King & Parke (1976).
Washed liver microsomes were diluted 10:1 with,O.IM tris 
buffer pH 7,6 to give a protein content of 1-2 mg/ml. Micro­
somes (id ml) were accurately pipetted into one,compartment 
of a pair of quartz 1 cm divided cells with an E-Mil green- 
line pipette. Substrate (l.O ml) dissolved in buffer to 20, 12, 
8, 4 and 2 mM, was pipetted into the second compartment of the
sample cell, buffer (l.O ml) being substituted in the reference 
cell. The visible spectrum of the sample versus reference cells
spectrophotometer (Cary I7 ; Varian; U.S.A.) and the difference 
spectrum then recorded after inverting and mixing the 
contents of both cells.
(o ) The oxygen electrode
Tho oxygen electrode consisted of a Clarke electrolytic 
cell employing a platinum cathode, silver/silver chloride anode 
and a Tefi.on, oxygon-permeable membrane (Diagram 3 Plate 4).
The polarographic voltage set across the coll was O .5 volts. 
Output current was monitored on a Porkin-Elmer 56 Pen recorder.
The response time of the cell was improved by a small 
glass-bead magnetic stirrer which under optimum conditions 
improved diffusion of oxygen to the electrode and also dis­
persement into the incubation mixture of microsomal fragments 
which could have clogged the membrane.
The top of the electrode consisted of a bubble trap 
which could be screwed down flush with the solution allowing 
any small bubbles of air to be trapped and expelled and 
thus reducing diffusion of atmospheric oxygen.
Rates of oxygen depletion were measured in the presence 
and absence of substrates which included asulam and the test- 
compound aminopyrine. The effect of high levels of background 
oxygen uptake was counteracted in part by the addition of nor- 
dihydroguariaretic acid (l mM) an inhibitor of lipid peroxidation.
Incubation conditions were as follows. The incubation 
mixture consisting of glucose,6-phosphate (3 mM), nicotin­
amide (50 mM), MgClg (20 mM), liver microsomes and phosphate 
buffer at pH 7*4 (50 mM) in a final volume of 2.0 ml, was 
allowed to equilibrate at 37°C for 5-10 minutes until 
oxygen tension was stable and the pen-recorder output was 
steady. NADP was then added from a 100y*1 Hamilton syringe 
and the bubble trap pushed into position.
DIAGRAM 3
An oxygen polarograph incor-porating membrane-covered electrode 
(after Clarke)
Expanded diagram of oxygen electrode, showing the major 
component parts.
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The rate of background oxygen consumption was found 
from the slope registered on the pen-recorder. Further 
oxygen consumption obtained after addition of 2 1 of
asulam or test-compound was similarly measured. Care was
taken not to introduce any small bubbles of air into the 
incubation mixture while delivering solutions through the 
top of the electrode.
The effect of adding small amounts of oxygen dissolved 
in solutions of substrates to the electrode during" 
incubation, was born in mind and volumes of such solutions 
were accordingly kept below 10 1.
Calibration of the electrode was achieved using phenyl- 
hydrazine hydrochloride and potassium ferricyanide by the 
method of Misra and Fridovich (1975)«
3. Results
The metabolism of asulam with liver enzymes is demon­
strated by histograms (Figures 1 and 2) which represent 
the relative activity of the various fractions produced 
as specified from a single batch of rat liver homogenate.
The absolute value of activity is the maximum limit of 
confidence for each result. Error in each measurement 
was calculated from the standard deviation for all control 
samples in each assay procedure.
The separation and identification of a hydroxylated 
metabolite produced from asulam-(ring during incubation
in vitro with liver microsomes, is given (Figures 3 and 4). 
Confirmation of structure by mass spectrometry and 
absorption spectroscopy, is given in Figures AlO/C, AlO/D & 83«
The binding of asulam and test-compounds to oxidised 
cytochrome P 450 is given in Table 1. Data from difference
spectra are used to express the type of spectra obtained 
and the respective spectral binding constants.
Tho oxygen uptake recorded following addition of 
asulam to microsomes in the Clarke oxygen electrode is 
given in Table 2. Discussion of results with respect 
to measurement of oxidation rate is given in Appendix 8.
Analytical data, calibration plots, difference spectra 
and regression analytical data appear in Appendix 8, •
A C T I V I T Y  
(/Jl/g/h )
•1
A S U L A M S U L P H A N IL A M ID E S U L P H A M E T H A Z IN E
1 1
1. W h o le  h o m o g e n a te
2  M i t o c h o n d r i a  a n d  n u c l e i
3  l O O O g  s u p e r n a t a n t
5 C y to s o l
n
1 2 3 5 T2 3 5 1"2 3 5
F R A C T IO N  N U M B E R  ( A r b i t r a r y  u n its )  t  N e g l ig ib le  a c t i v i t y
The metabolism of asulam and test-compounds by liver enzymes
(a) Acétylation
Substrate (30 AiM) was incubated in the presence of 
acetyl-S-CoA (20 alM). Tris buffer pH 6.8 (70 mM) and five 
fractions from 25^ rat liver homogenate (O.I-O.3 mg protein) 
in a final volume of 1.0 ml, for I5 m at 37°C after when 
the reaction was stopped with 2.0 ml trichloracetic acid 
(5^)» A control experiment was run concurrently in which 
acetyl-S-CoA was emitted. The incubation mixture was 
centrifuged and 0 .1^ (w/v) sodium nitrite (0.2 ml) added 
to 2.0 ml of supernatant. After 3 minutes excess nitrite 
was removed with 0.5^ (w/v) ammonium sulphamate (0.2 ml). 
After a further 3 minutes free substrate (unacetylated ) 
was coupled with 0,05^ (w/v) N-1-(napthyl)-ethylanediamine 
(1.0 ml) and the intensity of coloured product measured at 
540 nm.
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The metabolism of asulam and test-compound by liver enzyme
(b) Hydroxylation
Substrate'(5 mM) was incubated in the presence of 
NADP (1 m^), glucose-6-phosphate (25 mM), glucose-6-phosphate 
dehydrogenase (2 units), MgClg (20 mM), Tris buffer pH 
7.6 (80 mM) and three fractions from 25/^  rat liver homo­
genate (0.1-0.3 mg protein) in a final volume of 1.0 ml, 
for 15 m at 37°C after when reaction was stopped with 2.0 ml 
trichloracetic acid (5^). A control experiment was run 
concurrently in which NADP was omitted. Final incubation 
mixtures were centrifuged and 2.0 ml portions of supernatant 
were analysed according to substrate (^SEE Text^
FIGURE 3
14.TItc in vitro hydroxylation of %isulam-(rinr: C)
Developed radiochromatocram of ethyl acetate extract 
from incubation B8.
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TABLE I
The binding of asulam and test-compound to cytochrome P 450 
Asulam, test-compounds and washed liver microsomes in 0.1M tris 
buffer pH 7*6 were scanned between 54O and 520nm in a dual beam 
spectrophotometer, Microsomes ( 1-2mg/ml) and substrate (l-10mM) 
were mixed in one cuvette and both cuvettes were rescanned to obtain 
the difference spectrum. .
Substrate Spectrum Ks
(M)
No spectral -
Asulam interaction
Aniline Type II 2.19 X 10”^
Sulphanilamide . Type II 5.80 X 10"^
• -
TABLE X
Interaction of asulam with oxidation processes at the 
molecular level - measurement of reaction rate (K)
Asulam (0.5uü) was incubated at 37°C in the presence of NADP 
(éOOyîj), glucose-é-phosphate (5mM). magnesium chloride (2(Ml), 
nicotinamide (50kM), phosphate buffer pH 7.4 (50mM) and washed liver 
microsomes (0,6mg protein), with or without nordihydroguariaretic 
acid (NBGA) (imM)» in a final volume of 2,0ml, Rates of reaction 
of the freely oxidising, stirred incubation mixtures were recorded 
with the oxygen electrode. (For experimental data see Appendix Jo).
Run Microsomes Substrate Inhibitor Reaction rate 
K ( W h )
1 - - - 0,076
2 + - - 1,07
3 + + - 1.10
4 + - + 0.683
5 + + + 0.765
Summary of results
Studies with fractions from rat liver horaogenate, 
containing the drug metabolising enzymes and additives 
show that : -
(a) asulam is acetylated by an enzyme which is associated 
with cell-walls, nuclei or mitochondria. The pattern of 
metabolism is different both to sulphanilamide and sulpha- 
methazine which are metabolised mainly in the cytosol,
(b) asulam is hydroxylated by preparations of micro­
somes -to produce a compound which is separable from asulam
on thin-layer plates.and which does not produce the fragmentation ' 
profile of 2-hydroxyasuIam (major ions m/o = 197&214 at 200-230°C)
(c) though asulam is hydroxylated in vitro in micro­
somes, it does not demonstrate a positive binding spectrum 
with oxidised cytochrome P as does aniline and
sulphanilamide (K^ = 2.19 x 10 and 3.80 x 10 respectively), 
drugs which are also hydroxylated by microsomes.
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1. Conclusions about the fate of asulam
The dose is rapidly eliminated from intact animals 
in urine (77^) and faeces (7^)* Urinary metabolites com­
prise unchanged asulam (65^), N^-acetylasulam (lO^) and 
N^-acetylsulphanilamide (2^). Acétylation of asulam occurs 
principally in the liver, yet the hepatic enzymes are unable 
to form significant levels of hydroxylated metabolites in 
the intact state in vitro. A hydroxylated product is 
formed readily in isolated microsomes, though asulam does 
not exhibit any binding spectrum with oxidised cytochrome 
P 450.
The following discussion will attempt to analyse this 
problem and investigate its relationship with current trends 
in research on the drug-hydroxylating enzymes.
2. Some anomalies and interesting observations
(a) Sex-difference in metabolism
There occurs a sex-difference in acétylation of asulam 
in rats, male rats excreting more total acetylated metabolites 
(14.7^ dose - 2.9 S.D.) than females (9«3^ dose - 1.8 S.D.).
(b) Metabolism in the gut
4
Asulam is metabolised in the gut to give N -acetyl- 
asulam (circa 4^ dose) and N^-acetylsulphanilamide (circa 
0.2^ dose ) .Decarbamoylation of unchanged drug and metabolites 
to sulphanilamide and N -acetylsulphanilami'de, which is 
located specificly in the gut and probably mediated by bacteria, 
is slower than ace.tylation but the process may be induced 
by long-term administration of asulam.
(c) Occurence of an artifact
Under the conditions used the following artifacts may 
occur. Aqueous samples of drug and related metabolites
tend to form acid-labile water-soluble conjugates, formation
of which is promoted by storage at neutral pH. These so-
called conjugates break down in solution or on thin-layer
if
plates to give asulam, N -acetylasulam or other closely 
related metabolites.
3. The enzymology of drug hydroxylation
(a) Microsomes
The "enzyme" that mediates in the Phase I oxidation 
of drugs in mammals (villiams, 1959)» which has been called 
the mixed-funetion oxidase (Mason, 1957) or mono-oxygenase 
(Hayaishi, 1968) has been located in the endoplasmic 
reticulum of hepatic cells and in particular the smooth 
endoplasmic reticulum (Axelrod, 1955» Brodie et al, 1955»
Mitoma et al, 1956). Preparation of endoplasmic reticulum 
in an isolated state after homogenisation and differential 
centrifugation causes the bulk of it to fragment and form 
vesicles. Study of morphology of the vesicles which are 
known as microsomes and their wide-spread use to demonstrate 
the common drug hydroxylation reaction, has confirmed that 
little loss of activity is met if standard isolation procedures 
are adhered to (Pa lade & Siekevitz, 1956; Siekevitz, 1963)*
Structural analysis of microsomes isolated by the above 
procedures show that they contain lipid ( 40^), protein 
(• 45^) and nucleic acid (12-15^). The nucleic acid derives 
originally from rough endoplasmic reticulum(containing 
ribosomes) which is co-extracted with smooth endoplasmic 
reticulum and does not play any part in foreign compound 
metabolism. Microsomal lipid from rat liver is composed 
of 80-85^ phospholipid, about 10^ cholesterol, about 5/° 
triglyceride and approximately 1^ cholesterol esters and
free fatty acids (Schulze & Staudinger, 1975).
(b) The oxidation reaction
The hydroxylation of foreign compounds is a two-electron 
transfer from reduced nicotinamide nucleotide and two- 
electron change in the oxidation state of the substrate 
to form a hydroxylated product
RH + Og + NADPH +   ROH + H^O + NADP*
/RH = substrate^
^ROH = hydroxylated product/
(Estabrook et al, 1971b),
The reaction is specific for NADPH and therefore 
additional co-factor must be added to achieve maximum 
activity in vitro as normal extraction procedures cause 
the washing away of endogenous NADPH.
The closely-related pyridine nucleotide NADH will 
not substitute for NADPH as the co-factor for microsomal 
hydroxylation of foreign compounds, but NADH is known to 
be involved in other oxidation reactions in the microsomes 
and has been linked with microsomal steroid and lipid 
metabolism (Schenkman, Jansson & Robie-Smith, I976). 
Interestingly, the addition of NADH in the presence of 
NADPH causes a synergistic effect on hydroxylation of 
foreign compounds. Possible mechanisms for involvement 
of these co-factors in drug hydroxylation will be discussed 
in a later section.
Molecular oxygen is the oxidizing agent in the enzymatic 
hydroxylation but under certain conditions this may be 
replaced by organic hydroperoxide (Hrycay & O'Brien, 197^> 
Kadlubar, Mofton & Ziegler, 1973i Rahimtula & O'Brien, 1975)» 
Peroxides have a significant part to play in hydroxylation
of foreign compounds as they may form an alternative pathway 
for hydroxylation in the cell during periods of oxygen 
"starvation".
(c ) Biological components of the enzvme complex 
The protein of endoplasmic reticulum is made up of 
cytochromes containing the common haem prosthetic group 
and flavoproteins containing the flavin prosthetic groups 
flavinemononucleotide and flavineadeninedinucleotide.
In 1958 Klingenberg and Garfinlcel (1958) first 
identified a new cytochrome in liver microsomes. Further 
study of the ultra-violet spectrum of the cytochrome (Omura 
& Sato, 1964a ; Omura & Sato, 1964b) showed binding to carbon 
monoxide caused a peak at 4$0 nm in absorbance spectra of 
reduced cytochrome. The cytochrome, subsequently named 
P 450, was shown to be the agent of hydroxylation in liver  ^
microsomes (Estabrook, Cooper & Rosenthal, 19^3; Omura et 
al, 19655 Klingenberg, 1958).
Under control conditions, in the absence of foreign 
compounds, cytochrome P450 makes up 7^ of protein of the 
endoplasmic reticulum, or 0,1 mM per gram wet weight of 
liver (Estabrook, Shigematsu & Schenkman, 1970) but following 
pretreatment with phénobarbital this may increase to about 
20^ (for review on "induction" see Remmer, 1972).
Drugs may interact with the microsomes by binding to 
the haem group of cytochrome p450, a process which produces 
a conformational change in the ligands around the haem- 
iron and a corresponding change in absorption spectra.
Lipid-soluble compounds cause a decrease in the oxidised 
form of cytochrome P450 and a shift in the Soret band of 
the oxidised cytochrome (Kinoshita & Herie, I967» Remmer
et ai, J-yoo; ueinnier et aj., iyoo; bnenicman, Koramor & ivstaorooic, 
1967)• Aniline and similar basic compounds cause a shift 
in the Soret band towards the visible spectrum. Discussion 
of the various types of binding spectra will be taken up in 
a following section.
The remaining components of the microsomal mixed 
function oxidase are mainly involved in electron transport 
The finVOproteins NADPH-cytochrome c reductase and NADH- 
cytochrome reductase mostly act as specific dehydrogenases . 
in the presence of reduced co-factor. The main role for 
cytochrome b^ is unclear but it is linked with the electron 
transport chain to provide a role for NADH to act as a 
synergist for hydroxylation in the presence of NADPH 
(Hildebrandt & Estabrook, 1975) but a more probable role 
is in oxidation of exogenous substrates (Schenlcman, Jansson 
& Robie-Smith, 197^)«
(d) Experimental models for electron transport 
Estabrook et al (Estabrook et al, 1971a) proposed a 
scheme of cytochrome p450 reduction/oxidation cycle associated 
with hydroxylation reactions which took into account change 
in valence state of the iron in the haem group,
S
Fe**-S
Son
Fe’^ —  SoH
HjP
F e - ^ - > 5V
S  — e«xbsbrole.
Fe — c^ totWfort^  P4S0  
grcvp
The same authors suggested a role for cytochrome 
in acting as a donor for reducing equivalents to cytochrome 
P4^0 . TJius as either NADPH cytochrome c reductase or NADH 
cytochrome b^ reductase can provide the second electron, 
the synergising effect of NADH Is explained.
NADPH -------- > fp_  > cytochrome b '
, cytochrome
NADH --------- » fp£  ;-» X  > P450-— --» Og
fPl ^ 2 are flavoproteins ; X = unknown intermediate
An unknown intermediate is included to indicate an 
unknown carrier functional in transferring reducing equivalents 
from cytochrome b^ NADPH-cytochrome c reductase to cyto­
chrome Pk50,
(e) The involvement of lipid; Stierbhypothesis 
The hypothesis of Stier (stier, 1976) envisages a 
special conformation of enzyme components in the microsomal 
lipid membrane.
The cytochrome and flavoproteins which make up the 
multi-enzyme complex are envisaged as being interlinlced 
with each other in a rosette-like assemblage of protein 
and lipid. In particular, cytochrome P4$0 reductase or 
NADPH-cytochrome c reductase is surrounded by cytochrome 
PU50 which can maintain the required proximity to allow 
the electron transfer process to occur. Membrane phospho­
lipids bind the protein sub-units together in a halo of 
lipid.
Stier ' s hypothesis relies on the peculiar property 
of lipid to undergo a phase shift which changes lipid- 
packing in the membrane (shimstick and McConnell, 1973)«
A local shift in lipid structure by binding at a receptor 
site on the lipid can trigger a structural change throughout 
the membrane, thus effecting conformation of co-operative 
enzyme groupings which are embedded in the membrane.
This process of decoupling can be brought about by 
the binding of lipophilic substances, such as foreign 
compounds, to receptor sites on the lipid membrane or on 
the lipoprotein complex of the cytochrome system.
Formation of substrate complexes with cytochrome P4$0 are 
known to occur and this also according to the Stier's 
hypothesis can in turn effect a phase shift and bring about 
decoupling.
There is good experimental evidence that two forms of 
enzyme activity can exist in microsomes. In the case of 
biphenyl hydroxylation in guinea pigs (McPherson, Bridges 
& Parke, I976), the normal mode of metabolism by cytochpome 
PU50 gives 4-hydroxy biphenyl but pre-incubation of micro­
somes with an induction agent such as safrole causes pre­
dominant formation of 2-hydroxybiphenyl. The change in 
sterochemistry is emplained as being due to induction of 
cytochrome P448 which possesses different enzyme properties 
to cytochrome P450.
Stier's hypothesis concludes by reasoning that drugs 
may be able to change the physical state of the microsomes 
and decouple the enzymes of electron transport and therefore 
modify the specificity and orientation of metabolism. In 
the coupled state the flavoprotein is assumed as acting 
predominantly as a cytochrome P450 reductase and the cyto­
chrome as a hydroxylase or singlet oxygen superoxide anion 
peroxide (Parke, unpublished communications). In the
decoupled state the flavoprotein could act asan hydroxylase 
(Aust, Roerig & Pederson, 1972) and the cytochrome as a 
peroxidase (Kadlubar, Norton & Ziegler, 1973; Rahimtula & 
O'Brien, 1975) • Stier then concludes that as a consequence 
of the shift to a new equilibrium, substrate, ligand and 
inhibitor binding to cytochrome P4^0 could be different 
in the coupled and uncoupled states. It may be inferred 
from this that metabolism by flavoprotein in the fully 
decoupled state could proceed without formation of a binding 
spectrum.
h . Interaction between drugs and microsomes
(a) The haem group
The haem group is made up of an iron atom surrounded 
by a single substituted tetra-pyrrol group or porphyrin.
The iron is arranged centrally with four nitrogens from 
the heterocyclic rings forming four planar ligands so 
leaving the iron in a hexagonal configuration, with two 
available liganding positions at right angles to the plane 
of the porphyrin group.
In cytochrome P450 the haem is attached as a prosthetic 
group to the protein, giving a hemoprotein of molecular 
weight about 50,000. According to recent models (Collman 
& Sorrell, 1975; Koch et al, 1975) the haem group of cyto­
chrome has one of its six co-ordinating positions linked 
to protein through a mercaptide bond.
When the haem group is oxygenated, a molecule of 
oxygen occupies the fifth or sixth co-ordination position, 
binding to iron. In the same reaction the valence state 
of iron changes from ferrous to ferric. On passing from 
the five co-ordinated state to the six coordinated state,
the change in electronic configuration around the metal can 
be followed by B.S.R. by which iron is seen to change from 
high to low spin state.
Oxygon bonded to the haem group can be easily displaced 
by carbon monoxide (Klingenberg, 1958) or reducing agents 
such as sodium dithionite. The.oxygen in oxidised cyto­
chrome p4-50 is available for reaction with protein-bound 
substrates following the reaction scheme of Estabrook et 
al (1971a).
(b) Formation of the substrate-cytochrome complex
Hydroxylation of drugs usually is understood as proceeding
via prior formation of a substrate/cytochrome complex in 
the microsomes which is accompanied by shift in the maximum 
of the absorption spectra in the Soret band to longer ( type 
l) or shorter (type Xl) wavelengths (Schenkman, Remmer & 
Estabrook, I967).
Binding of type I substrates occurs in the neighbour­
hood of the sixth co-ordination position on the haem group, 
keeping the ferric cytochrome in a five co-ordinated high- 
spin state and causing displacement of the mercaptide group.
Type II substrates interact leaving the cytochrome in 
a low-spin state in which the liganding atom of the lipophilic 
compound is directly bonded at the sixth ligand position 
(Griffin, Smith & Peterson, 1974).
(c) Anomalous binding spectra
Most binding spectra are purely of a given type, 
either type I or type II, but some spectra show anomalous 
behaviour. Aniline gives a type II spectrum but has also 
been shown to give type II with an underlying component 
of type I (schenkman, 1970; Imai & Sato, 19^7; Gorrod &
Temple, 1973 ) « Type I and T>'’po IT binding may take place
simailtaneouRly thus lending to the possibility of mutual 
interference of two spectral absorbtions resulting from 
binding of different'substituent groups on a compound.
The phenoraenum of concentration-dependent binding- 
spectra is common with N-substituted amphotnnines, Inter­
action at low concentrations causes a type I spectrum which 
changes to type II at higher concentrations of drug (Hoff- 
strom & Orrenius, 1973)« This anomalous behaviour is 
consistent with interaction of amphetamine with cytochrome 
p450 at two separate sites. Higher affinity at the type 
•I site and the presence of endogenous substrates at the 
alternative type II site nay explain the complex spectra 
obtained.
Some spectra show additional absorption peaks in the
Soret region between 4-30 and 470 nm (Nishibayashi, Omura
& Sato, 1966;Imai & Sato, I968; Estabrook et al, 1971i
Ullrich & Schnatel, 1973)« They are formed with strong
ligands and electron-donating groups interacting with
reduced forms of cytochrome P450 to produce stabilized
substrate-cytochrome complexes. A more detailed account
of these reactions lies outside the scope of this thesis
and will not therefore be attempted.
(d) Relationships between binding and hydroxylation
Aminopyrine and hexobarbital both form type I binding
spectra with oxidised cytochrome P4$0 and Schenkman et al
(schenkman, Remmer & Estabrook, I967) found good agreement
between K^, the spectral binding constant representing
half-maximal concentration for staturating the binding site,
and K , the Michaelis-Menton constant for half-maximal m ’
enzyme activity, A link between binding to the cytochrome 
and hydroxylation was thus demonstrated. The type II 
substrate aniline on the other hand, gave ^ which has 
been explained as representing hemochrome formation 
(schenkman, Remmer & Estabrook, 1967). The type XI binding 
site therefore may not be as closely associated with the 
active site as in the case of type I metabolism.
The appearance of a binding spectrum for the type I 
substrates ethylmorphine and hexobarbital was not'observed 
following digestion of microsomal lipid with phospholipase 
C, an enzyme which specifically hydrolyses the main lipid 
constituents of microsomal membrane. Substrate hydroxylation 
in the same experiment was lowered by only 40^ (Chaplin 
& Mannering, 1970). Type II binding of aniline to the 
digested fragments was increased significantly, while 
hydroxylation was decreased by 15^« In another experiment 
the hydroxylation of aniline was activated by the non-ionic 
detergent Tifeen 80 %>rith no increase in the type II spectrally 
apparent complex (Burke, Bridges & Parke, 1975).
5 . Mechanisms of hydroxylation
Binding spectra have been used extensively to yield 
information about intermediate formation during metabolism 
of foreign compounds by the drug-metabolising enzymes.
Compounds that form complexes with haem usually contain 
a strong ligand such as nitrogen. The first compound 
for which a type II spectra was reported was aniline (imai,
& Sato, 1967), but other compounds containing phosphorous 
(e.g. diethylphenylphosphine), sulphur (e.g. octanethiol, 
pentamethylene sulphide), selenium (e.g. diethyl selenide), 
and oxygen (e.g. tetrahydrofuran) give nitrogen-like type
II spectra with washed microsomes (Ullrioh, Nastainczyk &
Ruf, 1975).
Aniline and substituted anilines have been studied 
in guinea-pig liver microsomes (Gorrod, Disley & Temple,
1971i Temple, 1971) rabbit liver microsomes (Gorrod &
Temple, 1973: Hlavica, 1972) and human liver microsomes 
(Kamataki, Kitada & Kitagawa, 1971). Sp^ hybridised lone- 
pair electrons of the nitrogen atom are involved in binding 
to the cytochrome and electron withdrawing groups in the 
ring cause lower binding constants— as does the steric 
hinderence of N-othyl or N,N-diethyl groups— converting the 
spectra from type II to type I. Products of C-hydroxylation 
were found to give type II spectra while those of N- 
hydroxylation gave type I spectra, showing a direct link 
between binding and metabolism. A full survey of many 
N-alkyl and N,N^-dialkyl anilines has'recently enabled 
correlations between structure and N- and C-oxidation to 
be made (Gorrod, Temple & Beckett, 1979). The effect 
of the modifiers hexobarbital and imidazole increased the 
magnitudes of type II and type I spectra respectively and 
transformed the type I spectrum of N-ethylaniline to a 
type II spectrum.
The absolute binding spectra of amphetamines (Kawalek 
et al, 1976; Franklin, 1976) have showed strong interaction 
with oxidised cytochrome p450. Difference spectra of (+) 
and (-) amphetamines (Hoffstrom & Orrenius, 1973) exhibited 
a concentration-dependenee during binding. When (+)- 
amphetamine concentration was increased the spectrum changed 
from type I to type II, showing competitive inhibition with 
an endogenous substrate on the type II binding site.
The absence of a binding spectrum for barbital N-methyl- 
1.barbital and N,N -dimethylbarbito 1 (Topham, 197Q) contrasts 
strongly with phénobarbital and hexobarbital which were 
both found to give type I spectra. Metabolism of barbiturates 
by oxidative déméthylation was observed without the necessity 
of spectral interaction.
An extensive survey of binding spectra of foreign 
compounds (Mailman & Hodgson, 1972; Mailman et al, 197^5 
Kulkarri, Mailman & Hodgson, 1975) demonstrated type I 
spectra formation by carbamate pesticides. In contrast 
N-methylacetamide gave a type II spectrum, which showed 
that benzene or other bulky aromatic groups could bind at 
the type I site.
The binding spectra of sulphonainides have not been 
widely studied. A complex with cytochrome p 450 with 
maximum at 450 nm was found when sulphanilamide was incubated 
with microsomes but the difference spectrum was not determined 
(Franklin, 1976). Sulphadimethoxine gave no detectable 
binding spectrum with rat liver microsomes (Sickel &Steele, 
1974).
6. The metabolism of asulam
(a) Nature of the cellular barriers
The metabolism of asulam in the rat depends initially 
on successful transport or penetration through the common 
cellular barriers. These include the plasma membrane 
encasing each cell, the lining of the gut or barrier of 
cells between the gut and intestinal blood capillaries, 
the environment of lipid surrounding enzymes of the endo­
plasmic reticulum.
These structural elements will be briefly described
prior to a more detailed analysis of the ionisation and 
transport of asulam,
(i) Plasma membrane
The established model for biological membranes after 
Davson and Danielli (Davson & Danielli, 1952) regards the 
outer ce11-wall membrane, or plasma membrane, as a lipid- 
bilayer bounded and held together on each side by adsorbed 
protein. The protein is seem as providing structural 
strength and stability while the tightly paeked-together 
lipid chains act as a phase barrier to diffusion of molecules 
through the membrane.
(ii) Gut wall
The lining of the gut, through which all food is 
absorbed, consists of a cellular layer, two or three cells 
thick, between the gastro-intestinal tract and the blood 
capillaries.
(iii) Endoplasmic reticulum
The endoplasmic reticulum is strictly not a membrane 
but still offers an effective barrier to transport in the 
vicinity of the drug-metabolising enzymes and in particular 
to the active-site of the enzymes. It consists of protein 
and lipid laying in juxtaposition in a longitudinal matrix. 
The model of the drug-metabolising enzymes of the endoplasmic 
reticulum proposed by Stier (1976) is briefly reviewed in 
a previous section. The close proximity of lipid and 
protein can be reduced by structural changes in the lipid 
phase.
(b) Charged species in solution
The difference in water-solubility between asulam 
free-acid and its salts is very marked. The high
solubility of the sodium, potassium and alkaline earth 
metal salts, up to 4o^ v//v 80 times more soluble than 
asulam (Hey^jood 6 Leeds, I968) may be due in part to a large 
negative free energy of formation of the hydrated asulam 
anion.
A possible explanation for this is the increase in
ionic entropy gained on passing from the free acid in
solution to the hydrated ion. The asulam molecule can be
regarded as a roughly linear backbone containing a. benzene
nucleus and oxy groups protruding outwards from the
chain. The para-substituted aniline and carbamate
groups constitute hydrophobic and hydrophilic centres
respectively. The sulphonyl group also has
hydrophilic properties but its proximity to
the aromatic electron clouds and the comparatively low
dipole moment of the sulphur-oxygen double bond may lessen
its ability to interact with solvent molecules.
0 0 
HgN-^^S-NH-C-OCH^
0
Hydrophobic 
regi on
Hydrophilic
region
In the unionized state, the dipoles on oxygen will
attract opposite dipoles in the surrounding water molecules.
On loss of a hydrogen ion from nitrogen the effective
electronic charge on oxygen of the oxy groups will be
greatly increased by resonance.
e ©
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The negative charge will attract a greater number of 
water molecules which would be accommodated in a solvent- 
cluster of maybe two to three molecules with their hydrogens 
forming hydrogen bonds around the carboxyl group. More 
water molecules will form a second layer with dipoles 
aligned towards the anionic centre and they in turn attract 
more molecules. Therefore the ionisation of asulam has 
produced an effective ordering of the solvent molecules 
in the hydrophilic region. It is also true that hydrogen 
bonding could also take place at nitrogen or on the sulphonyl 
group. Three factors would disfavour this kind of inter­
action in favour of bonding at oxygen, namely the larger 
size of the nitrogen ion with corresponding lower electronic 
charge at the ion surface, the higher electronegativity of 
sulphur leading to lower polarisation along the sulphur- 
oxygen bond and also steric hindrance of the benzene ring 
laying in the plane of the sulphoxy groups and of adjacent 
groups around nitrogen.
The stability of asulam either in the charged or 
uncharged state will depend on the sum of ya, the chemical 
potential or molar free energy, of the ions in solution.
This is composed of contributions from the enthalpy and 
entropy of the system. (For a more detailed review, see 
Guggenheim, 1957). Of these two contributions entropy 
is the greater as ionisation only results in.the breaking 
of a nitrogen-hydrogen bond, which is in fact facilitated 
by formation of a double-bond by resonance.
Asulam in the unionised form in solution would interact 
with the surrounding water molecules in the manner suggested 
but, lacking an ionic centre, it would cause a lower ordering
of solvent molecules than the anionic form and thus 
contributions to the ionic entropy by the hydrophobic 
portion of the molecule would become more significant.
Thus the existence of molecules of the free acid in solution 
would disrupt solvent-solvent hydrogen bonding causing 
greater disorder so that dissolving of the free acid would 
lead to a positive change in entropy. The charged state 
ifould thus become thermodynamically most stable.
Calculations of ionization made for asulam in Appendix 
1, show that formation of the anion is favoured at neutral 
pH and that the cation is formed below pH2.5* The model, 
based on spectroscopic measurement of pk at varying pHs, 
only shows an average stationary-state distribution of the 
charged species. In the dynamic system in practice, asulam 
is continually losing and gaining a hydrogen ion from solution, 
as the ionization energy must be very low. At the 
physiological pH of ?.4, encountered in blood plasma and 
in the cells of the liver, formation of the free acid will 
take place albeit at a low rate.
In acidic solutions encountered in the gut, and in 
neutral solutions of free acid outside the body, the tendency 
of asulam to adopt the ionized form in solution is satisfied 
by formation of a zwitterion
The isoelectric point for asulam, as predicted by the 
Henderson-Hasselbalch equation, and as found in practice 
(Heywood & Leeds, I968) occurs around pH3«3i the pH of upper 
regions in the small intestine. At this pH thermodynamic
con.triDucxons in tne asuiam moxecuie may oe mainiy uue 
to the doubly charged zwitterion, bearing in mind the 
still significant contributions to ionic entropy available 
by solvent interaction with the charged centres on both 
the nitrogens. The equation, however predicts that at a 
pH of 3»3> less than lO^ o of asulam molecules will be ionized. 
It follows therefore that asulam exists at pH 3»3> mostly 
as the free acid but that some stabilisation is offered 
by formation of the zwitterion. This may explain why 
asulam is not readily precipitated from solutions of sodium 
asulam which have been adjusted to pH 3*3* Precipitation 
of the free acid may be offset by the zwitterion which 
may aid supersaturation. (The reason for the poor solubility 
of asulam may in fact be due to high lattice energy.)
The solubility of asulam at the iso-electric point 
will be lowest. Conversely, in a lipid environment such 
as that found in the membranes of cells solubility will 
be increased.
(c) Penetration through membranes
The penetration of non-electrolytes through lipid 
membranes depends on the compound first dissolving in the 
membrane lipid and then in the aqueous phase on the other 
side. Asulam exists mostly in an ionic state at 
physiological pH and so membrane transport is restricted 
to the small fraction of molecules which, in the equilibrium 
state, are in the free acid form. The magnitude of this 
equilibrium is about 100:1 in favour of the anionic form 
under normal conditions in the blood. This means that 
as only the uncharged lipophilic molecules can penetrate 
the membrane, the rate of asulam transport into the intra­
cellular space will be low. A mechanism may exist, however 
to speed up transport.
will contain basic amino-acid residues, some orientated 
away from the membrane and occupying the membrane-plasma 
interface. A weakly acidic moleéule such as asulam, 
ionised in the initial state, could pick up a hydrogen-ion 
from the amino-acid residue on passing towards the membrane. 
Similarly, membrane protein on the inside of the cell-wall 
could interact with the migrating species so that a hydrogen- 
ion is left on an unionized basic amino-acid residue. V/hen 
asulam has penetrated the lipid barrier in the membrane 
its tendency to re-dissolve in the aqueous environment of 
the cytosol will be low as its hydrophobic properties 
will loosen the order of solvent molecules and lead to an 
increase in entropy. If asulam could exchange a hydrogen- 
ion with the membrane by the above mechanism, transport 
would be greatly facilitated.
X P^+H^N-^^^SO^-NH-CO^CH^ + X®
P — protein 
§ — counter-ion
On passing through the membrane in the uncharged 
state, asulam would find itself ih the ionic state at the 
lipid-cytosol interface. Once in the cytosol, the formation 
of strong hydrogen bonds would counteract the tendency 
for the free acid to remain dissolved in the lipid bilayer.
The observed increase in volume of distribution to 
129 ml in the perfused liver and corresponding uptake 
of drug by liver cells and erythrocytes can be explained 
by the above mechanism of facilitated diffusion. The 
concentration of asulam in the red blood cells was 
olmoat equal to that in plasma. The following results 
were obtained:
\Pesults
Part-
itioning\ 
Ph a R \
Volume
contribution
in
perfusate
(ml)
^ dose 
after 36O 
minutes 
perfusion
^ dose/ 
volume
Sc A
K
^lA
K
Red cells 
(RC) 35 30 1.167
1 1.4 4.2Plasma (P) 65 52.5 0.808
Liver (l ) 5* 17 3.400 )
"'’concentration of total metabolites
♦volume of intracellular fluid/10 g rat liver (spector,
1956).
Asulatn is clearly taken up by cells in the blood and 
liver, and is somewhat concentrated in liver. Some sul- 
phonamides are known to reversibly bind to protein and this 
may be in evidence to some extent in liver, yet the remarkably 
rapid equilibration of asulam in about 10 minutes in red 
cells (see Figure 1, Chapter U) calls for an efficient mode 
of membrane transport. It is suggested that this transport 
follows the mechanism described.
The appearance of acetylated metabolites takes place 
only in the presence of liver. (N o 'metabolism of asulam 
occured in the perfusate during a blank experiment)
Production of the acetylated metabolites follows first 
order kinetics for up to five hours. Hydroxylated products 
are also formed but metabolism follows zero-order kinetics. 
Acetylated and hydroxylated metabolites of asulam can form 
charged species in solution by ionization at acidic 
nitrogen. Thus a similar transport pattern to asulam 
might be expected. In this case the observed kinetics 
suggest that asulam acétylation is a slower process than 
transport of products into the plasma and that hydroxylation
takes place by a concentration-independent mechanism, the 
back-diffusion of hydroxylated product through the semi­
crystalline lipid lattice of the membrane maybe is a 
relatively slow process (stein, I962).
(d) Interaction with enzymes
The following metabolites of asulam have been identified 
in incubations with the liver enzymes, N^-acetylasulam 
(XXIl) formation is mediated by an enzyme situated in the 
cell membrane fraction of liver homogenate.
H ^ C O C H N - i ^ ^ S O ^ - N H - C O ^ C H ^  H O H N - ^ ^  S O ^ -N H -C O ^ C H ^
(XXII) (XXIII)
(XXIV)
This metabolite is also found in vivo as well as in the perfused 
liver and seems to be the major metabolite of asulam in 
the species studied. Identification of the N-hydroxy 
metabolite (^IIl)and 3-hydroxyasulam O^iv) is somewhat 
tentative as only very small amounts of hydroxylated 
metabolites were formed in vivo. Evidence was also obtained 
of their unstability in solution.
During thin-layer chromatography of the extract from 
liver -microsomes small amounts of an intensely coloured 
blue material were observed, running at about the same rf 
as the oxidised metabolite. It is proposed that this offers 
further evidence of N-oxidation of asulam. The proposed 
mechanism follows those described for the SNl rearrangement 
of phenylhydroxylamines in aqueous solution (Hughes 
& Ingold, 1952),
Under acidic conditions phenylhydroxylamine forms a 
carbanion by picking up a hydrogen ion and splitting off
water. The resulting imino immediately reacts with water 
forming the ring substituted phenol. For asulam this can
be proposed os follows (sequence I ):
R - Q y - N H - O H ^   — ----- > R - < Q - N H
H
“  H^o " ' R - ( I ^ N H 2
H H 2
R^-SOgNKCOgCHn 
Once the aminophenol has been formed, further reaction
may occur as described for the air oxidation of aminophenols 
to a phenoxazone on silica thin-layer chromatography plates 
(Gerber, 1968). Again, this can be proposed for 3-hydroxy­
asulam as follows (sequence II):
R = -SOgNHCOgCHg 
The 2-phenoxazones are reported to show a strong 
absorbance in the region 3^5-3^5 cyt (schafer, W., Progr. in 
org.Chem. (1964), 6, 135)»
It is impossible to say whether N-hydroxy asulam originally 
gave rise to 2-phenoxazones since any 3-hydroxyasulam formed 
in incubations would also give rise to the same product.
What is clear, is that these blue products show conclusively 
the presence of 3-hydroxyasulam . in solution, whether it 
be formed by metabolism or by prior rearrangement of N-hydroxy-
^ K j  j. j. a ijxjitxj  6  — a u u A V ^ L U L U U  n y  U  I* U A  y  U  S  u x  a f j l
could not take part in 2-phenoxazone synthesis (sequence II) 
and by consideration of the reaction mechanism, could not
be formed by rearrangement of phenylhydroxylamine (sequence T)
A problem may exist in reconciling the apparently
contradictive results obtained by thin-layer chromatography 
on the one hand and colorimetric assay on the other, as 2- 
hydroxyasulam was initially used to develop the assay 
procedure for hydroxyasulams, The problem may be resolved 
if one recognizes that either 2-, 3- or N-hydroxyasulam 
would give a positive colour with diazotised sulphanilic 
acid. The yellow product formed between diazotised sul­
phanilic acid and hydroxyasulams formed in the rat could be 
the following species
0
R - < ^ ^ N  .= N -<^)-SO^H R hQ > -  N = N - ^ y  SO^H
^OH
The maximum absorbance of 430 nm of the coupled species 
in the assay mixture strongly suggests the existence of 
diazines. Reaction would take place at primary or secondary 
substituted nitrogen contained in all three considered 
hydroxy asulam metabolites. The assay may hot then, be 
specific for 2-hydroxyasulam alone.
Once the nature of hydroxylated metabolites has been 
fixed, certain problems arise as to their production by 
the enzyme and to what extent interaction with the drug- 
metabolising enzymes effects the extent and type of 
metabolism, taking into account the absence of any observable 
spectral interaction with the cytochrome. The problem 
can be put more into perspective by refering to Stiei*s 
hypothesis of decoupling of the cytochromal electron 
transport chain,but also by firstly considering the fate
of aniline.
In the perfused rat liver aniline becomes well- 
metabolised forming in three hours conjugates of p- 
aminophenol (l3/° dose) which are eliminated in the bile 
(Boobis & Powis, 1975)» In homogenates aniline is well 
known to form similar hydroxylated metabolites (Parke,
I96O; Wills, 1971). When the rates of aniline metabolism 
are compared with those of asulam metabolism as measured 
in this project a change in relative activity arises between 
the in vivo and in vitro states. Though asulam is hydroxy­
lated slower than aniline in the perfused rat liver (maximum 
4 ,5^ in 5 hours) with no appreciable elimination of metabolites 
in bile ( 1^ dose), in vitro with fortified microsomal 
suspensions, contrastingly, the hydroxylation rate outstrips 
that of aniline by a factor of four. This raises the 
question why are the mechanisms for asulam hydroxylation 
different in vitro and in vivo?
Interaction between asulam, in the charged anionic 
form, and the lipid barrier of the endoplasmic reticulum 
would be expectedly low, especially if no energetically 
stable substrate-cytochrome complex were formed. The 
charged anions would prefer to remain in maximum contact 
with solvent molecules in the cytosol and breakage of 
hydrogen bonds with water, necessary on passing towards 
the lipid matrix, would be thermodynamicly unfavourable.
Even so, asulam molecules may align themselves somewhat to 
allow interaction between the lipid-rich areas of the 
endoplasmic reticulum and the 4-amino group which can 
interact with the lipid. Any small interaction of this 
nature may be very dependent on the relative amounts of
drug and microsomos. A very low degree of drug-lipid 
binding at a relatively low concentration of drug may be 
completely reversed or radically altered by a change, 
induced by the drug, of lipid packing in the microsome.
At low concentrations of asulam, such as that obtained in vivo 
and in the perfused liver, minimal interaction with micro­
somes might be expected. When asulam concentration is 
relatively high the asulam molecules may become orientated 
to a small extent at the lipid-water interface similar to 
a surface active agent, as the competition for water 
molecules in the cytosol becomes greater and as asulam- 
lipid interactions become more predominant, A change in 
lipid packing or phase shift (shimstick & McConnell, 1973; 
Stier, 1976) could cause the cytochrome P450 system to 
decouple. The resulting change in enzyme characteristics 
and activity would explain the apparent change in asulam 
metabolism.
7 . Asulam-quiescent substrate or decoupling agent?
The question remains, is asulam incapable of binding 
to cytochrome p450 or does binding produce an anomalous 
spectrum? In this context the term quiescence could be 
used to describe the following behaviour. Asulam may 
bind to the haem through the 4-amino group giving a type 
II absorption but it is also at the same time, equilibrated 
between binding at say a lipophilic site on the cytochrome. 
This introduces a type I component similar to the type II 
aniline spectrum. The two types of absorption would 
effectively cancel each other out as the type I absorption 
maximum (38O nm) co-incides roughly with the type II 
absorbtion minimum (390 nm) in the difference spectrum.
Asulam therefore appears*to be inactive while still binding
and therefore acting as a substrate with cytochrome P450.
The more likely answer to the lack of a binding spectra, 
based on results obtained in vitro is that asulam, at a 
relatively high concentration can trigger re-structuring of 
the lipid component in the endoplasmic reticulum and thus 
effect decoupling of the drug metabolising enzymes.
As previously discussed, asulam forms a charged anionic 
species in solution at physiological pH, with the charge 
delocalised by resonance but mostly centred around the 
carbamoyl oxy group. The free acid also exists in solution 
in dynamic equilibrium with the ionized form at the level 
of 0.5^ to 1.0^ of total compound. Asulam may be partitioned 
between lipid and water at the membrane-cytosol interface. 
Formation of asulam-lipid hydrophobic bonds through the 
unionized 4-amino group, may serve to break up lipi'd-lipid 
binding in the overall membrane structure and hence lead to 
decoupling of the enzymes of the electron transport chain.
The concentration of asulam in the vicinity of the 
endoplasmic reticulum may effect the phase shift in lipid.
When the amount of asulam in solution is increased, the 
drug-lipid interactions will become more significant, at 
the expense of the membrane lipid-lipid interactions. In 
the experiments with asulam, concentrations of drug in solution, 
are higher in vitro though estimation of drug concentrations 
in vivo is difficult. The volume of intracellular fluid 
is 0.67 ml/gm wet weight of liver (Spector, 1956).
Knowing the partition of asulam between plasma and liver 
intracellular fluid (4.2), the relative concentrations of
asulam at the enzyme surface can be calculated for each 
experiment.
Experiment
Asulam concentration 
(mg/ml)
(l) Single dose; no
pre-medication 0.84
(2 ) Single dose; with
induction 0.84
(3 ) Liver perfusion
/
0.40
(4) In vitro
(a)Colorimetric assay 1.2
(b)Long-term incubation 2.3
(c)Oxygen electrode 2.3
(d)Spectral studies 2.3-4.6
The difference in asulam concentrations between in vivo 
and in vitro experiments may be important in triggering a 
phase shift in the lipid of the endoplasmic reticulum, 
but other unknown factors may also be involved. At low 
concentration the hydroxylation of asulam occurs extremely 
slowly due to basicly low affinity for the enzyme site on 
the lipid membrane. As the concentration of drug in 
solution is raised the amount of asulam at the lipid- 
water interface increases which may lead to à phase shift 
in the membrane caused by the hydrophobic bonding with 
the 4-amino group. Affinity for the subsequently decoupled 
enzyme could be greater and asulam thus becomes hydroxylated 
freely in the new enzyme conformation.
Hydroxylation of asulam is thus proposed as taking 
place by two mechanisms dependent on the concentration of 
drug relative to the drug metabolising enzyme. Production 
of N-hydroxyasulam probably takes place after decoupling in
concentrated solutions of asulam, by a flavoprotein which 
could be NADPH cytochrome c reductase or NADP cytochrome 
b^ reductase. The N-hydroxy metabolite would rearrange 
to 3-hydroxyasulam in solution and during solvent extraction 
at acid pH, The two unidentified polar conjugates in 
perfusates from liver could be the N- and C-hydroxylated 
products,
The alternative suggestion that asulam is a normal 
substrate but is inactive in producing a typical binding 
spectrum, is unlikely. The expected formation of a type 
II ligand at the sixth position on haem by the 4-amino group, 
which occurs in both aniline and sulphanilamide, would 
be stericly hindered by the charged carbonyl group. The 
haem group on cytochrome p450 seems an unlikely site for 
binding of asulam.
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APPENDIX 1 Ionic state of asulam
nenoerson-nasseipaicn equation ior percentage ionised species
(i) lonisable groups
The two amino groups are in different chemical environ­
ments. The N^-amino adjacent to carbonyl and sulphonyl 
is effectively acidic. The aromatic N^-amino is similar 
to aniline and is weakly basic. For the purposes of the 
derivation ionisation of the N^-amino group represents
formation of the anion or the salt of a weak acid and
4 a
that of the N -group, formation of the -NH- cation or the
i
conjugate acid of a weak base.
(ii) The equation
This states that: 
pH = pK^ + L»*10
Extent of ionisation, say X, of a single ionisable 
group, say n, can be found at various pHs given pK 
the acid dissociation constant for the group, so that:-
= Xn Log^o'l(pH - pKa)
From a previous reference (Heywood & Leeds, I968), 
pK for the N^-amino group equals 4.82 and pK for the 
N^-amino group formerly given as dissociation constant for 
the base (pK^), equals 1.80 given that pk^ = l4 - pk^.
(iii) Graphic representation
Ionisation of a dissociable group can be represented 
by plotting the variation of percentage ionisation (I ) 
with pH. I can be found from the Henderson-Hasselbalch 
equation as follows:-
It^ = X and /salt/ + ^aoid/ = 1
^acid/
therefore ^salt7 = ^ ^ ^ /acid? - ^ ^ ^
Then percentage ionisation is given ass- 
l(l) (N^-amino) =
1 (2 ) (N^-amino) =
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APPENDIX 2 Preparation of asulam-(ring
Labelled benzene is firstly converted to aniline and 
the amino group protected by acétylation to form acetanilide.
.NO^  Np, NHCÛCH3
CPgCOgH
The para substituted sulphonaraide is then prepared
by chlorsulphonation of acetanilide to 4-acetamidobenzene-
sulphonylchloride and substitution of an amino group to 
4
give N -acetylsulphanilamide. During chlorsulphonation 
of acetanilide some of the sulphanilic acid is formed 
which may be converted back to the amino derivative by a 
two step process.
3
NHCOCH NHi -
SOI Cl S’O^NH
PCINHCOCH
pyridine
The final stage involves removal of the acetyl group 
with alkali to give sulphanilamide and reaction of this 
with dimethyl carbonate to give asulam.
NHCOCH NH
OH
NaOCH
SO^NH SOUNH
The main impurities are sulphanilamide, formed by- 
hydrolysis of asulam in solution and 4-methylcarbamoyl- 
benzenesulphonlycarbamate, formed as a by-product during 
chlorsulphonation. Purification of product can be achieved 
by precipitating the ammonium salt from a solution of the 
free acid in acetone. Further removal of labelled 
impurities is effected by stirring a solution in methanol 
with anion exchange resin. These procedures can give 
in a typical synthesis a purity of not less than 58.5^, 
measured by reverse isotope dilution or thin-layer 
chromatography (see Figures 1 and 2),
FIGURE 1 Chromatography,of starting material
Asulam-(ring____ç); batch DUA 2572
'Qr:!
i i . :  :  I
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FIGURE 2 Chromatography^of starting material
Asulam-(ring " C ); batch DUA 2613B
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APPENDIX 3 Preparation of some putative metabolites
(a) Acetylasulam-(ring
The compound is synthesised by a similar pathway to that 
described for asulam-(ring (Appendix 2) except that
the penultimate stage, removal of the N-acetyl protection 
group from the substituted 4-amino position on the benzene 
ring, is omitted the final product being produced directly 
by the reaction between dimethylcarbonate and acetylsulph- 
anilamide.
NHCOCHNHCOCH
NaOCH
Purity was established by thin-layer chromatography on 
silica gel (Polygram SILG/UV^^^ with development in ethyl- 
acetate/diethylether/acetic acid (glacial)(5:5:1, by volume) 
and IS estimated at 96.4% (figure 3).
(b) Acetylsulphanilamide-(ring ^^c)
Small amounts were prepared biochemically by dosing 
rats with asulam-(ring ^^c) and isolating the metabolite 
from urine. Purity was established at 75*8^ by thin-layer 
chromatography on silica gel (Polygram SILG/uv^^^) (Figure 4) 
with development in toluene/ethanol (3:1, v/v).
Rats were dosed with 10 mg/kg asulam-(ring ^^c)
(15 /tCi/rat). Urine was collected for 48 hours and extracted 
five times with equal volumes of ethyl acetate at pH3.
The organic fractions were bulked and evaporated free of 
solvent under vacuum at 35^C. Methanolic solutions of 
the concentrated metabolites were spotted on a preparative
grooved thin-layer chromatoplate i^ M&B ChromolayJ containing 
silica at 0,5 mm thickness. Metabolites including N - 
acetylsulphanilamide-(ring were separated into bands
by development in isopropanol/ammonia solution (S.G.0.88) 
(lO:l, v/v) and were scraped off the plate and shaken 
for lOmin with water, N^-ace tylsulphanilamide - ( ring ) 
was re-extracted from the washings into ethyl acetate 
at pH3 and re-chromatographed, to effect a rough purification, 
in toluene/ethanol (3:1, v/v) the final product being 
deabsorbed from the silica with water and returned to 
ethyl acetate by further extraction at pH3, Radiochemical 
purity of the final product was estimated by thin-layer 
chromatography and reverse isotope dilution.
(c) Acetylasulam (cold)
A similar pathway as for the labelled compound can be 
used with aniline as starting material.
(d) Acetylsulphanilamide (cold)
A similar pathway as described above for acetylasulam- 
(ring ^^c) can be used with aniline as starting material, 
omitting the final two stages.
(e) 2-hydroxyasulam (cold)
This is prepared by a six stage procedure, starting 
with 2-amino,,5-nitrophenol. Firstly the hydroxy group 
is protected by a benzyloxy group to produce 2-benzyloxy- 
4-nitroaniline.
NO
K-CO./Kl/PhCH„Cl
in acetone OCH„PhOH
NH NH
beconaiy a sulphonyl group is substituted for the amino
group by diazotlsation and reaction with sulpher dioxide
in the presence of copper chloride and this is further
modified to a methyl sulphonyl carbamate group by reaction
of the sulphonamide intermediate with methyl chloroformate. 
NO.
^ (ijHCl/NaNOg/HOAL
(2)ChCl2/S02/H0AC OCH Ph
SOgCl ^
NO NO.
NH^(aq) K^CO^/ClCOOMe
S0_C1
Uv I in acetone
^OCHgPh OCH.,Ph T "^"2OCH„Ph
SOgNHg SOgNHCOOCHg
The final reduction is effected in two steps. Titanium 
chloride is used for reduction of the nitro group and the 
benzyloxy group removed under reducing condition over 
palladium/charcoal.
NO
^ TiCl^(aq) ^ ^ H^/Pd.C
->
OCH,Ph" "ethanol 
S O ^ S o ^  SO2NHCOOCH3 SO^NHCOOCH.
A colourless crystallised product with melting point 
l45-l46°C was obtained by the above procedure. 
/Theoretical: 39.02#C, 4.0?^H, 11.38#N, 13.01?oS; Actual: 
38.7^0, 4.2^H, 11.35bN, 13.2#s7
FIGURE 3 Chromatography of reference compound
N ~acetylasulam-(ring c); batch EMQ 396
c :
4. >
FIGURE h Chromatography of reference co^^ound
N -acetylsulphanilamide-(ring C );
preparation A
ia
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APPENDIX 4 Analytical recovery data
O K S  a  A. £» U X l ^ t ^ U
samples
(i ) Labelled compounds
The following compounds were used for recovery experi­
ments from male and female rats:-
(1) A 3ulam-(ring ; batch DWA 2Ô13B was used through­
out. Purity was 99*79° by thin-layer chromatography 
(Figure 2). Solutions for spiking were prepared by 
dissolving approximately 4 mg in methanol (25 ml).
(2 ) N^-acetylasulam-(ring ; batch EMQ 396 (O.l
mCi/mM) was used throughout. Purity was 96.4^ by thin- 
layer chromatography (Figure 3 ) the compound being 
prepared by acétylation of a.sulam-(ring ) (see Appendix
3 ). Solutions were prepared by dissolving approximately 
6 mg in methanol (2.5 ml).
(3 ) N^-acetylsulphanilamide-(ring ): preparation 
A obtained from urine of rats dosed with asulam-(ring 
batch DWA 2572 (see Appendix 3 ). Purity was 75*8^ by 
thin-layer chromatography (Figure 4). Solutions were 
prepared in methanol.
(ii) Urine
5 ml of blank urine was spiked with 0.1 ml of a solution 
of labelled compound and extracted at pH3 three times 
with equal volumes of ethyl acetate in a 10 ml measuring 
cylinder.
(iii) Faeces
Approximately 5 g of faeces was spiked with 0,1 ml 
of a solution of labelled compound and dried overnight 
in vacuo. Representative sub-samples (l g) were then 
extracted by the method previously described in the text
(chapter 2, experimental section)
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APPENDIX 5 Single-dose studies
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APPENDIX 7 Perfusion studies
Kinetics of elimination irom periused liver 
Equation for elimination constant (k)
If drug elimination is first-order then 
= C q exp (-kt) 
where Cq = concentration of drug at time 0 
Co. = concentration of drug at time t 
Therefore taking logs.
In = In Cq - kt .
So k can be obtained as the slope and Cq the y intercept from 
a straight line plot of In C^ versus t,
C. can be measured by assaying for unchanged drug in 
plasma samples taken from the perfusate at varying intervals 
(t).
Equation for volume of distribution and clearance rate
The volume of distribution (Vd) is given by
Vd = Quantity of drug (p)
Initial concentration (Cq ) (ll)
Vd is usually quoted in ml”^ therefore if D and C^ are
measured in ju. moles and yu, moles/1 respectively then (ll)
becomes
Vd = 1000 D (III)
Co
The clearance rate (k) is given by
k = Volume of distribution (vd) x Elimination constant (k)
Weight of liver (vT)
Time is measured in hours therefore if k is in hr ^
-1 -1 -1
and W in grammes then K will be expressed as ml hr ,g
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FIGURE 49 Chromatography of organic extract of aqueous
residue D from plasma/perfusate
Enzyme blank Expt, 1
i t : x
FIGURE 50 Chromatography of organic extract of aqueous
residue D from plasma/perfusate
Enzyme blank Expt, 2
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FIGURE 51 Chromatography of organic extract of aqueous
residue D from plasma/perfusate
Bovine liver enzyme Expt, 1
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FIGURE 52 Chromatography of organic extract of aqueous
residue D from plasma/perfusate
Helix Pomatia enzyme Expt, 2
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FIGUHE 53 Chromatography of organic extract of aqueous
residue from plasma/perfusate
Helix Pomatia enzyme Expt. 1
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FIGURE 54 Chromatography of organic extract of aqueous
residue D from plasma/perfusate
Bovine liver enzyme Expt. 2
I : : 'iO: , !
nfM-ri-H-h
■ ! I . I-;
FIGURE 55 Chromatography of re-eluted peak material
from neat plasma
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FIGURE 56 Chromatography of re-eluted peak material from 
bile
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FIGURE 58 Chromatography of aqueous residue B of
perfused liver
FIGURE 59 Chromatography of organic extract C from
plasma/perfusate
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FIGURE 60 Chromatography of bile (reference f )
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FIGURE A8/B Enzyme assay for hydroxylation 
Calibration plot for sulphanilamide 
(refer to measurements sh, s 6  & S?)
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FIGURE A8/C
Absorption spectra of hydroxylated asulam (assay procedure') 
Coloured product formed with diazotised sulphanilic acid at (l)
60uM and concentration of 2-hydroxy asulam
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Figure AS/o
The Mnding- of asulam and test-compo\mds to cytochrome P-450 
Calculation of Kg (Cox et al, 1976) was achieved for aniline and 
sulphanilamide only, from the absorption data available.
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FIGUIÎI? 61
Difference spectrum of washod liver microsomos
Substrate; Asulam 2mM (ref a8)
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FIGURE 62
Difference spectrum of washed liver microsomes
Substrate; Asulam lOmM (ref A9)
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FIGUlîE 63
Difference spectrum of washed liver microsomes
Substrate: Sulphanilamide 2mM (ref S8)
04i
FIGURE 64
Difference spectrum of washed liver microsomes
Substrate: Sulphanilamide 4mM (ref S9)
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FIGURE 65
Difference spectrum of washed liver microsomes 
Substrate; Sulphanilamide 6mM (ref SlO)
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FIGURE 66
Difference spectrum of washed liver microsomes
Substrate ; Aniline lmM(ref, An8)
4 5 o4oo
ÛO ol
FIGUÎiE 67
Difference spectrum of washed liver microsomes
Substrate: Aniline 2mM (ref An9 )
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FIGURE 68
Difference spectrum of wnshed liver microsomns
Substrate: Aniline (ref AnlO)
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FIGURE 69
Difference spectrum of washed liver microsotnes 
Su'bstratei Aniline (ref Anil)
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FIGURE 70
Difference spectnam of washed liver microsomes
Substrate: Aniline 10 miî (ref Anl2)
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Difference spectrum of washed livnr mi crosomoc;
Substrate: Blank
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APPENDIX 9 Stability studies
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APPENDIX 10 Mass Spectrometry
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Mass Spectrometry of N^-acetylasulam (Figure M O / a )
Major Fragment Ions
m/e Structure m / e Structure
272 CH^CO-HM-^SOg-m-COgCH^lt 156
2h0 CH^CO-HN-^SOg-N=C=0^t 151 c h ^c o -h n - ^ o hI î
230 l4o © - 302"'
21k ^^Og-NH-COgCH^lt 135 CH^CO-HN-0lt
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Mass Spectrometry of N^~acetylsulphanilamide (Fi/yure AIO/B)
Major Fragment Ions
m/e Structure m/e Structure
21^ CH^CO-HN-^ SOg-KHgl t l4o ^ S O /
198 ciyco-HN^Qy-sOg'*' 109 HgN-©- Oult
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Mass Spectrometry of 2-hvdroxyasulani (Figure AlO/c)
• Major Fragment Ions
m/e Structure
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APPENDIX 11 Measurements with the oxygen electrode
The OxYi'^ en Electrode
(a ) Introduction
Factors which affect oxygen uptake from microsomal 
incubations are dependent on oxidative processes in the 
microsomes (Orrenius et al, 1964) and are usually in­
dependent of oxygen concentration in solution.
The utilization of oxygen in a sealed incubation 
consisting of microsomes, substrate and required co-factors 
may be given as follows : -
(1) oxygen consumption of electrode: The electrolytic 
reduction of oxygen at the platinum cathode continues
during operation of the electrode.
(2 ) endogenous oxygen-utilizing processes in 
microsomes; These may be NADPH-linked such as the common 
autoxidation process of lipid peroxidation. They can 
be induced by the addition of co-factor (Vi 11s, I969),
The magnitude of background oxygen consumption during in­
cubation may be reduced by the addition of the food anti­
oxidant nordihydroguariaretic acid (NDG-A).
(3 ) oxidation of substrate; Substrate oxidation 
is NADPH-dependent and therefore may compete directly with 
lipid peroxidation.
(b) Measurements with the Clarke Electrode
The oxygen content of a standard incubation mixture 
used with the Clarke oxygen electrode at 37°C, is made 
by measuring the pen deflection obtained after addition 
of a small aliquot of a solution of phenylhydrazine (Misra 
and Fridovich, 1975).
The total oxygen concentration c is given by
c = ^ ^ where v - aliquant (ml)
2 X V
y = total pen deflection (cm)
X = deflection due to phenylhydrazine (cm)
V = incubation volume (ml)
For the calibration experiment v = 40; y = 22.4 5 ;
X  = 11.83; V = 2.
Therefore c = 190 id'I.
The use of the Clarke electrode for measurement of 
reaction rates is more complex. Interpretation of a single 
measurement of oxygen depletion from solution may be made 
using the following assumptions;-
(1) reactions contributing to total oxygen utilization 
are additive
(2) inhibition of lipid peroxidation by NDGA, is 
non-competitive i.e. independent of substrate concentration.
(3) separate inhibiting effects of NDGA and sub­
strate on lipid peroxidation are additive and non-interacting.
(4) rates of oxygen consumption in incubation 
mixtures of microsomes, substrate and inhibitor can be 
expressed by linear combinations of various 
constants of reaction and inhibition.
(c ) Derivation of expressions for oxygen uptake 
Oxygen uptake in the freely operating Clarke electrode 
may be represented in part by the following constants of 
reaction and inhibition;-
= oxidative processes in the microsomes which
include NADPH-linked lipid peroxidation 
kg c oxidation of substrate
p = inhibition of lipid peroxidation and other
oxidative processes in the microsomes by substrate 
q = inhibition of lipid peroxidation and other oxidative
processes in the microsomes by NDGA 
= oxygen consumption of electrode (blank)
Kg = oxygen consumption of microsomes plus NADPH 
(background)
= oxygen consumption after addition of substrate
to microsomes plus NADPH
= oxygen consumption of microsomes plus NADPH
plus NDGA inhibitor
Kg = oxygen consumption of microsomes plus NADPH plus
NDGA after addition of substrate
The relationship of the above constants according
to the assumptions made are as follows;-
Kg = + k^ (microsomes alone)
Kg = + pk^ + kg (microsomes + substrate)
+ qk^ (microsomes + inhibitor)
Kg = + pqkj^ + kg (microsomes + inhibitor + substrate)
Solution of the above simultaneous equations leads to
the following expression;
kg = rate of substrate oxidation = Kj^(K^-K2+K|^-Kg) + (KgKg-K^K|J
(Kg K^)
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77 Incubation with washed liver microsomes in the
oxyfcon electrode; Chart ref, no. 1
FIGTOE 78 Incubation with washed liver microsomes in the
oxyfcen electrode; Chart ref, no. 2
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FIGURE 79 Incubation with washed liver microsomes in the
oxygen electrode; Chart rnf. no. 3
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FIGURE 80 Incubation vith vashod liver microsomos In tne
•oxygon electrode; Chart ref, no» 4
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FIGURE 81 Incubation with washed liver microsomes in the
oxygon electrode; Chart ref. no» 5
FIGURE 82 Incubation with washed liver microsomes in the
oxygen electrode; Chart ref, no» 6
APPENDIX 12 MISCELLANEOUS METHODS
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